THE ROLE OF ENHANCED POLYCOMB REPRESSIVE COMPLEX 2 ACTIVITY IN TUMORIGENESIS by L. Cedrone
 
 
PhD degree in Molecular Medicine (curriculum in Molecular Oncology) 
European School of Molecular Medicine (SEMM),  
University of Milan and University of Naples “Federico II” 
Settore disciplinare: MED/04 
 
 
 
The role of enhanced Polycomb Repressive Complex2 activity in 
tumorigenesis 
 
Laura Cedrone 
 
Istituto Italiano di Tecnologia, Milan  
 
Matricola n. R10317 
 
 
Supervisor: Dr. Diego Pasini 
Istituto Europeo di Oncologia, Milan  
 
 
 
 
 
Anno accademico 2015-2016 
 

1 
 
TABLE OF CONTENTS 
TABLE OF CONTENTS .....................................................................................................1 
FIGURES AND TABLES INDEX ......................................................................................5 
LIST OF ABBREVIATIONS .............................................................................................8 
ABSTRACT ........................................................................................................................13 
1. INTRODUCTION ..........................................................................................................15 
1.1. Chromatin Properties .............................................................................................15 
1.1.1. Overview of chromatin features. ........................................................................15 
1.1.2. Roles of the major histone and DNA modifications. .........................................17 
1.1.3. DNA methylation ...............................................................................................19 
1.1.4. Post-translational modifications .........................................................................19 
1.1.5. Histone methylation ...........................................................................................23 
1.2 Polycomb group of proteins and their role on chromatin ....................................27 
1.2.1 Overview of Polycomb proteins..........................................................................27 
1.2.2. Polycomb Repressive Complex 1 ......................................................................29 
1.2.3. Polycomb Repressive Complex 2 ......................................................................31 
1.2.4. Polycomb recruitment to target loci ...................................................................33 
1.3. Epigenetics and diseases .........................................................................................37 
1.3.1 Epigenetics and cancers ......................................................................................38 
1.3.1.1 DNA methylation .........................................................................................39 
1.3.1.2 Histone modifications ..................................................................................41 
1.3.1.2.1 Histone acetylation and cancer..............................................................41 
1.3.1.2.2 Histone deacetylation and cancer ..........................................................42 
1.3.1.2.3 Histone Methylation and Cancer ...........................................................43 
1.3.2 Polycomb and cancers .........................................................................................44 
2 
 
1.3.2.1 Lymphoma and gain of function EZH2 mutations ...................................... 45 
1.3.2.2 EZH2 as therapeutic target .......................................................................... 49 
1.4. Aim of the thesis ...................................................................................................... 51 
2. MATERIALS AND METHODS .................................................................................. 53 
2.1 Cell culture and manipulation. ............................................................................... 53 
2.1.1 Cell lines generation and growing conditions. ................................................... 53 
2.1.2 Transfection ........................................................................................................ 55 
2.1.3 Lentiviral infection ............................................................................................. 56 
2.1.3 Lentiviral vectors ................................................................................................ 56 
2.2 Techniques used for protein detection ................................................................... 57 
2.2.1 Immunoblot analysis ........................................................................................... 57 
2.2.2 Immunofluorescence. .......................................................................................... 58 
2.2.3 Mass Spectrometry analysis ............................................................................... 59 
2.2.4 Acidic extraction of histones and Immunopurification ...................................... 61 
2.2.5 In-gel digestion of histones for MS analysis ...................................................... 61 
2.2.6 Data analysis for histone PTMs MS/MS ............................................................ 62 
2.2.7 Cell cycle analysis with FACS ........................................................................... 64 
2.3 Assays for detection of DNA modifications and protein binding to DNA. ......... 64 
2.3.1 Chromatin Immunoprecipitation (ChIP)............................................................. 64 
2.3.2 ChIP Rx: Reference exogenous genome ChIP ................................................... 65 
2.3.3 High throughput ChIP sequencing (ChIPseq) .................................................... 66 
2.3.4 ChIP-Quantitative Real Time PCR (RT-qPCR) ................................................. 66 
2.3.5 ChIP sequencing data analysis............................................................................ 67 
2.4 Methods for RNA analysis ...................................................................................... 68 
2.4.1 RNA sequencing (RNA-seq) .............................................................................. 68 
2.4.2 RNA sequencing data analysis. .......................................................................... 69 
3 
 
2.4.3 Real Time quantitative PCR................................................................................69 
2.5 Reprogramming .......................................................................................................69 
2.5.1 Infection and selection of OKSM MEFs .............................................................69 
2.5.2 Reprogramming experiment................................................................................70 
2.5.3 Assessment of GFP+ colonies .............................................................................71 
2.5.4 Alkaline phosphatase staining .............................................................................71 
2.6 Antibodies .................................................................................................................71 
2.6.1 Antibodies used for Immunoblot and immunoprecipitation analyses.................71 
2.6.2 Antibodies used for ChIP analyses .....................................................................72 
2.6.3 Antibodies used for immunofluorescence staining and FACS ...........................72 
2.7 Primers ......................................................................................................................72 
3. RESULTS .......................................................................................................................75 
3.1 MEF model system ...................................................................................................75 
3.2 MEF harboring Y641N/F EZH2 show imbalance in H3K27 methylation status 
as in lymphoma cells ......................................................................................................76 
3.3 Distribution of H3K27 modifications and PRC2 localization ..............................79 
3.4. Relocalization...........................................................................................................82 
3.5. Transcriptional analyses .........................................................................................84 
3.6 The effect of EZH2 GOF mutations in response to stimuli ..................................87 
3.6.1 Myc-driven Polycomb activity ............................................................................88 
3.6.2 Starvation-driven Polycomb activity...................................................................92 
3.6.3 Reprogramming...................................................................................................95 
3.7 Validation in B-cell Lymphomas ............................................................................99 
3.7.1 Lymphoma cells ectopically expressing or physiologically harboring Y641N/F 
EZH2 show imbalance in H3K27 methylation status ..................................................99 
3.7.2 Distribution of H3K27 modifications in lymphoma cells .................................101 
4 
 
4. DISCUSSION ............................................................................................................... 105 
5. BIBLIOGRAPHY ........................................................................................................ 117 
6. ACKNOWLEDGEMENTS ........................................................................................ 142 
  
5 
 
FIGURES AND TABLES INDEX 
Figure 1: Mechanism of methylation. ............................................................................................ 24 
Figure 2: Biochemistry of the different PRC1 complexes. .................................................... 30 
Figure 3: Principal members of PRC2 complex. ....................................................................... 32 
Figure 4: Patterns of H3K27 methylation status in lymphoma cell lines harboring a 
WT of heterozygous mutant form of EZH2. ...................................................................... 47 
Figure 5: PRC2 complexes containing mutant EZH2 preferentially catalyze di- and 
trimethylation of histone H3K27. ........................................................................................... 48 
Figure 6: Schematic representation of the employed lentiviral vectors and 
experimental approach. .............................................................................................................. 76 
Figure 7: MEFs overexpressing mutant EZH2 rearrange H3K27 methylation 
balance. ............................................................................................................................................. 77 
Figure 8: EZH2 Y641N mutant needs its WT counterpart to alter the methylation 
status of H3K27. ............................................................................................................................ 78 
Figure 9: Quantification by mass spectrometry of H3K27 methylation status. ............ 79 
Figure 10: Traditional ChIP-seq analysis is not able to reveal an increase in 
H3K27me3 upon expression of the Y641N mutant. ........................................................ 80 
Figure 11: ChIP-Rx shows gain of H3K27me3 in MEFs overexpressing mutant 
EZH2. ................................................................................................................................................ 82 
Figure 12: H3K27me3 mark is relocalized to nuclear periphery upon overexpression 
of mutant EZH2. ........................................................................................................................... 83 
Figure 13: Expression profiling on MEFs expressing EZH2 WT and EZH2 Y641N 
does not show any differences between samples. ............................................................. 84 
Figure 14: Expression profile on MEFs expressing EZH2 WT and EZH2 Y641N 
shows differences when cultured at confluency. .............................................................. 85 
6 
 
Figure 15: Gene-ontology enrichment analyses reveals that upon confluency, there is 
downregulation of genes involved in cell adhesion and upregulation of genes 
involved in epithelial differentiation. .................................................................................... 86 
Figure 16: Validation of up- and down-regulated genes in MEFs expressing EZH2 
Y641N. ............................................................................................................................................... 87 
Figure 17: Schematic representation of the employed lentiviral vectors and 
experimental approach. .............................................................................................................. 89 
Figure 18: The mutant EZH2 Y641N alters methylation states on H3K27 also in 
3T3MycER MEF. ............................................................................................................................... 90 
Figure 19: Time and dose dependent-induction of Myc in MEFs expressing WT or 
mutated form of EZH2. .............................................................................................................. 91 
Figure 20: Expression profile on 3T3MycER MEFs expressing EZH2 WT or the mutant 
Y641N ................................................................................................................................................ 92 
Figure 21: FACS analyses show exit from the cell cycle when cells are grown in 
starvation condition. .................................................................................................................... 93 
Figure 22: Mutant EZH2 induces further accumulation of H3K27me3 mark in 
starved cells. .................................................................................................................................... 94 
Figure 23: Expression profile on MEFs expressing EZH2 WT and EZH2 Y641N 
shows few differences in starvation condition. .................................................................. 95 
Figure 24: Genes involved in early and late phases of reprogramming are enriched 
for H3K27me3 upon expression of mutant EZH2 Y641N in MEFs. ........................ 96 
Figure 25: Schematic representation of the employed lentiviral vectors and 
experimental approach for reprograming. ......................................................................... 97 
Figure 26: Mutant EZH2 impairs reprogramming. ................................................................. 99 
Figure 27: Lymphoma cells overexpressing or harboring mutant EZH2 rearrange 
H3K27 methylation states. ...................................................................................................... 100 
7 
 
Figure 28: Traditional ChIP qPCR analysis is not able to reveal increase in 
H3K27me3 upon expression of the mutant EZH2 Y641N. ........................................ 101 
Figure 29: ChIP qPCR analysis is not able to reveal increase in H3K27me3 in 
lymphoma cells naturally expressing mutant EZH2 Y641F enzyme. .................... 102 
Figure 30: ChIP qPCR analysis is not able to reveal increase in H3K27me3 in SU 
DHL6 cells that naturally express mutant EZH2 Y641N enzyme. ......................... 103 
Figure 31: Y641N EZH2 mutant expression causes the increased deposition of 
H3K27me3 in DLBCL. ............................................................................................................. 104 
 
 
Table 1: Summary of residues subjected to post-translational modification and their 
functional outcome. ............................................................................................................ 21 
Table 2: List of enzymes that induce epigenetic modifications ........................................ 22 
Table 3: Epigenetic regulators altered in cancer. ................................................................ 39 
Table 4: Primers used in ChIP qPCR. ................................................................................... 73 
Table 5: Primers used in RT-qPCR. ....................................................................................... 74 
 
8 
 
LIST OF ABBREVIATIONS 
4-OHT: 4-hydroxytamoxifen 
5caC: 5-carboxylcytosine 
5fc: 5-formylcytosine 
5hmc: 5-hydroxymethylcytosyne 
5mc: 5-methyl cytosine 
ALL: Acute lymphocytic leukemia 
ALS: amyotrophic lateral sclerosis 
AML: Acute myeloid leukemia 
APL: Acute promyelocytic leukemia 
ASXL1: Additional Sex Combs Like 1 
Bcl: B-cell lymphoma 
BCOR: BCL6 Corepressor 
BRCA: Breast Related Cancer Antigen 
BrdU: Bromo deoxy Uridine 
CBP: CREB binding protein  
ChIP: Chromatin immunoprecipitation 
ChIP-Rx: Chromatin immunoprecipitation with reference exogenous genome 
ChIP-seq: Chromatin immunoprecipitation-sequencing 
CpG: Cytosine-guanine dinucleotides  
CpGi: CpG island 
DNMTs: De novo methyltransferases  
Dpc: Days post coitum  
DZNep: 3-Deazaneplanocin A 
E[z]: Enhancer of Zeste 
9 
 
Eed: Embryonic Ectoderm Development 
EtOH: ethanol 
Ezh1/2: Enhancer Of Zeste 
FACS: Fluorescence Activated Cell Sorting 
GFP: Green Fluorescent Protein 
H2AK119ub: Mono-ubiquitination of the lysine 119 on the histone H2a 
H3K27me0: un-methylated histone H3 on lysine 27 
H3K27me1:mono-methylation of histone H3 on lysine 27 
H3K27me2:di-methylated of histone H3 on lysine 27 
H3K27me3:tri- methylation of histone H3 on lysine 27 
HAT: Histone Acetyltransferase 
HDAC: Histone Deacetylases 
HKMTs: Histone Lysine Methyltransferase 
HMTs: histone methyltransferase 
HP1: heterochromatin protein1 
ICF: Immunodeficiency, centromeric instability, and facial dysmorphism syndrome 
IGF2: Insulin Like Growth Factor 2 
iPSCs: Induced pluripotent stem cells 
IRES: internal ribosome entry site 
KDM1A (or LSD1): Lysine Demethylase 1A 
Kdm2b: Lysine Demethylase 2B 
Klf4: Kruppel-like factor 4 
LIF: Leukemia Inhibitory Factor 
LOH: Loss of heterozygosity 
MASPIN: Mammary serine protease inhibitor 
MBD: Methyl binding domain 
MDS: Myelodysplastic syndromes 
10 
 
Mecp2: Methyl-CpG binding protein 2 
MEF: Mouse embryonic fibroblasts 
mESC: Mouse embryonic stem cells 
MLL: Mixed lineage leukemia 
MS: Mass spectrometry 
NSD: Nuclear Receptor Binding SET Domain Protein 
PcG: Polycomb Group proteins 
PCGF: Polycomb group RING fingers 
Pcl: Polycomblike proteins 
PEV: Position-effect variegation 
PI: Propidium iodide 
PLZF-RARα: Promyelocytic leukemia zinc finger-retinoic acid receptor α  
PML-RARα: Promyelocytic leukemia-retinoic acid receptor α 
PRC1: Polycomb repressive complex1 
PRC2: Polycomb repressive complex2 
PRE: Polycomb response element 
Psc: Posterior sex combs 
PTMs: Post-translational modifications 
qPCR: Quantitative polymerase chain reaction 
RAR: Retinoic acid receptor 
RAREs: Retinoic acid response elements 
Rb: retinoblastoma 
RbAp46/48: Retinoblastoma protein associated protein 46/48 
REST: RE1-Silencing Transcription factor 
RIZ1: Retinoblastoma-interacting zinc-finger protein 1 
RNA-seq: RNA-sequencing 
RYBP: RING1 And YY1 Binding Protein 
11 
 
SAH: S-Adenosyl-L-homocysteine 
SAM: S-adenosyl-L-methionine 
Sox2: SRY-Box 2 
Suz12: Suppressor Of Zeste 12 Protein Homolog 
TET: Ten-eleven translocation 
TF: Transcription factor 
Trx-G: Trithorax Group proteins 
TSS: Transcription start site 
UT: untreated or Empty vector 
VEGFR: Vascular endothelial growth factor receptor 
WB: western blot 
WT: wild type  
YY1: Yin Yang 1 protein 
  
12 
 
  
13 
 
ABSTRACT 
Polycomb Group of proteins (PcGs), members of polycomb repressive complex 2 (PRC2) 
and polycomb repressive complex 1 (PRC1), are essential factors present in cells’ nuclei. 
These multiproteins complexes are key repressive factors that regulate cellular 
differentiation during development, contributing to the correct establishment of lineage-
specific transcriptional programs. Their repressive activities, linked to chromatin 
compaction and transcriptional repression, are regulated in a cell type-specific manner. They 
represent key factors of proliferation and a strong correlation between the deregulated levels 
or activity of PcG proteins and the development of several types of human cancers has been 
demostrated.  
Recently, gain of function (GOF) heterozygous EZH2 mutations have been discovered. 
These mutations are present in 7% of follicular lymphomas and 21% of cases of human 
diffuse large B-cell lymphomas (DLBCL) accounting for about 30-40 % of newly diagnosed 
cases of non-Hodgkin lymphomas. These mutations occur mainly on Tyrosine 641 within 
the EZH2 catalytic SET domain, causing an aminoacidic substitution from tyrosine to 
phenylalanine, serine, histidine or asparagine (Y641F, Y641S, Y641H, and Y641N). These 
mutations are responsible for the enhanced activity of EZH2 towards H3K27me3 deposition 
when the mutated form of the enzyme is accompanied by the wild type (WT EZH2) 
counterpart in lymphoma cells. In particular, the increase in H3K27me3 deposition is 
accompanied by a decrease in H3K27me1 and H3K27me2 levels. Up to now little is known 
about the mechanism of action of this mutated enzyme, therefore the aim of this thesis is 
trying to unravel the tumorigenic mechanisms underlying these mutations.  
To understand a general oncogenic role for this mutated enzyme, we took advantage of an 
alternative, simpler model system, represented by MEF, to perform our analyses. We then 
validated our results in lymphoma cell lines. We could show that, indeed, the increased 
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genome wide deposition of the H3K27me3 mark was valid also in an independent cellular 
setting. Surprisingly, this altered deposition was not accompanied by any relevant 
transcriptional alteration at steady state. To address this issue, we subjected MEFs to three 
different types of stimuli (starvation, myc upregulation and reprogramming to pluripotency) 
in the attempt to highlight a cooperative transcriptional de-regulation for mutant EZH2. 
Surprisingly, we found that the output of widespread trimethylation of K27 was evident only 
when cells transitioned from one cell fate to another, pointing to the blockade of upregulation 
of non-expressed genes during cell reprogramming. Thus, we hypothesized a sentinel role 
for the mutant EZH2 Y641N, in which the levels of the repressive mark H3K27me3 are 
increasingly deposited where the mark is already present at steady state. This could underlie 
mutant EZH2 functionality in DLBCL, where it could lock centroblasts in a “low-
differentiation” state in the germinal center and impede the up-regulation of specific factors 
important for their differentiation. This, in combination with other tumorigenic mutations, 
would lead to the onset of lymphomas in patients. If proven true, these results would link 
the epigenetic control cellular differentiation to tumorigenesis, shedding light on new 
druggable targets for improved care of patients. 
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1. INTRODUCTION 
1.1. Chromatin Properties 
1.1.1. Overview of chromatin features. 
DNA in eukaryotic cells undergoes multiple levels of hierarchical folding in order to be 
arranged into the nucleus. In this organelle the genome is highly organized and subjected to 
a high degree of compaction (from 10000 to 20000 fold) in order to fit in. The hierarchy, on 
the other hand, assures that all regions would be correctly accessible to be replicated in each 
cell cycle and to be subjected to the other DNA-based processes. The organization of DNA 
into chromatin ends up with the formation of chromosomes where the hyper-condensed 
chromatin structure is obtained through the tight association of DNA with histone and non-
histone proteins [1]. The basic unit of the chromatin fiber is the nucleosome. The discovery 
of the nucleosome date back to early seventies thanks to seminal work by Luger and 
colleagues through the use of X-rays diffraction. In particular, the nucleosome is composed 
by 147bp DNA, left handedly coiled around a complex of histone proteins that are called 
H2A, H2B, H3 and H4, and organized in an octameric structure in which H3-H4 tetramer 
associates to two adjacent H2A-H2B dimers [2]. This structure was firstly observed by 
Kornberg in 1974 [3, 4]. The combination of these nucleoproteins, joined together through 
a region of so called linker DNA, compose a structure similar to the “beads on a string” 
visible with electron microscopy [5]. The linker DNA between nucleosome particles may be 
associated with the linker proteins belonging to the H1 histone family [6, 7]. They are usually 
present in close proximity to where the DNA enters and exits from nucleosomes. These 
packed nucleosome arrays in association with linker histones and other chromatin-associated 
proteins allow the higher order organization of the chromatin in the nucleus. This is possible 
thanks to amino acids present in the positively charged nucleosomes, which let them interact 
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with the negatively charged phosphate group of DNA. Moreover, all histones (except H4) 
are present in different variants and different post-translational modifications (PTMs) can 
occur on them, dictating nucleosome positioning and the overall organization of chromatin. 
In the end they represent fundamental modulators of many cellular DNA-template processes 
such as transcription, replication, repair and recombination. Based on the timing of 
expression, we can distinguish two categories of histones: replication-dependent and 
replacement variants. The first ones, encoded by multiple genes copies, are clustered in the 
genome, are devoid of introns, do not present a poly (A) tail and their 3’-end present a stem-
loop conserved sequence responsible for the high rates of transcription of these proteins [8, 
9]. They are expressed in S phase, in order to assure a major supply for incorporation events 
during replication, and become part of chromatin during DNA synthesis. They are 
represented by the H3.1 and H3.2 genes. The replacement histone variants are generally 
expressed in tissue-specific manner and throughout the cell cycle; their mRNA can contain 
introns and are characterized by the presence of 3’-polyadenylated tails. They are 
represented by the human variant H3.3 encoded by the H3.3A and H3.3B genes. 
There are some molecules responsible for the incorporation of histone proteins in order to 
form the nucleosome particles. These factors are called histone chaperones [10]. Eukaryotes 
have evolved histone chaperones that can be specific for one or more histone variants. It has 
been shown that the same histones can have more than one chaperone in order to answer 
specifically to the processes taking place in a specific moment in the cell [11, 12]. For 
example, Asf1 is involved in chromatin assembly after double strand break repair [13], in 
chromatin disassembly before replication [14, 15] and chromatin disassembly during 
transcription [16-18]. FACT complex is responsible for the H2A–H2B dimer removal/ 
displacement [19-21]. Another chaperone is DAXX whose role is the incorporation of H3.3 
at telomeres [22, 23].  
Overall nucleosomes represent the key factor for DNA accessibility which is firstly 
determined by nucleosome position that allows the exposure of specific and precise portion 
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of DNA. Nucleosome positioning, determined by the deposition of PTMs on histones, is 
responsible for the higher or lower degree of compaction of chromatin affecting the levels 
of transcription. In particular, with respect to the degree of the compaction we can 
distinguish two chromatin types: euchromatin and heterochromatin. These two states of 
chromatin present differences from a cytological point of view being the euchromatin less 
intensely stained with respect to heterochromatin, the latter being characterized by a more 
compact form of DNA. Conversely the euchromatin is more relaxed and less folded, in line 
with its higher accessibility to the replication machinery. Indeed, heterochromatic 
configuration is commonly found on peripheral areas of the nucleus and correlates with a 
poorer transcriptional activity and, likely, with gene repression [24].  
These configurations are plastic and interchangeable, with specific proteins that are 
responsible for the high dynamicity of the chromatin structure [25]. These factors, called 
collectively chromatin remodelers, can induce specific changes in the shape of the 
chromatin, modulating its accessibility in response to different stimuli. 
 
1.1.2. Roles of the major histone and DNA modifications.  
Allfrey and colleagues showed for the first time the possibility that histone could be 
subjected to modification to alter transcription [26]. In particular they focused on two 
modifications: acetylation and methylation. Histones are characterized by two structurally 
and functionally distinct domains: the globular portion is the one implicated in the formation 
of the core of the nucleosome and the unstructured tail protruding from this core. First 
indications on how PTMs on these tails could affect the interaction between nucleosomes 
came initially from the work of Luger and colleagues in 1997 [2].  
Since then, there has been a massive effort to analyze, understand, characterize, and 
potentially to “use”, the enzymatic activities responsible for the deposition and removal of 
histones and DNA modifications. Histone modifications are able not only to regulate the 
18 
 
nucleosomes interaction but they are essential also for the recruitment of specific proteins, 
i.e. remodeling complexes. The PTMs and DNA modifications constitute the epigenetic 
regulation of cellular processes.  The term epigenetics was coined by Conrad Waddington 
in 1942 even two years before Avery, MacLeod, and McCarty demonstrated that the DNA 
was the source of hereditary information. Waddington defined epigenetics as “a branch of 
biology that study the casual interactions between genes and their products”. Riggs and 
colleagues defined epigenetics as “the study of mitotically and/or meiotically heritable 
changes in gene function that cannot be explained by changes in DNA sequence” [27]. A 
more recent definition, proposed by Levenson and Sweatt [28] links epigenetics directly to 
chromatin modifications using this definition: ”the mechanism for the stable maintenance of 
gene expression that involves physically “marking” DNA or its associated proteins” 
allowing “genotypically” identical cells to be phenotypically distinct”. Indeed, several 
chromatin-modifying factors play essential roles in regulating epigenetic phenomena such 
as gene imprinting and X-chromosome inactivation [29].  
The epigenetic world is composed by several characters identified as “writers” (and 
“erasers”), that catalyze the addition (removal) of chemical groups onto either histone tails 
or the DNA itself, “readers”, responsible to recognize and bind specific modifications and 
“targets” of the modification.  
Among the well-known “writers” there are the histone acetyltransferases (HAT) and lysine 
methyltransferases (KMT) about which I will discuss more deeply in next paragraph. 
Relative erasers are histone deacetylase and demethylases. 
 “Readers” are characterized by domains whose structure typically provides a cavity or 
surface groove to accommodate a specific epigenetic mark, such as lysine mono-, di- and 
trimethylation. One example is represented by CBX protein where its chromodomain can 
specifically recognize trimethylation on H3K27. 
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1.1.3. DNA methylation 
DNA modifications can regulate the association and the downstream functions of factors 
able or induced to bind DNA. In this sense DNA can be methylated on the cytosine at 
position 5 (5mc) in the context of CG dinucleotides. This modification is heritable and linked 
with gene silencing due to the fact that its presence impedes the interaction between DNA 
and transcription factors [30]. It acts also as docking site for protein harboring methyl 
binding motif (MBD) that can be chromatin remodelers and transcriptional co-repressor 
factors [31]. On the other hand, it is also true that all along the genome there are regions rich 
of CpG dinucleotides. This CpG islands are indeed maintained free of DNA methylation. 
About 60-70% of promoters contain CpG islands whose methylation would result in stable 
transcriptional repression [32]. These modification is catalyzed by a family of enzymes 
called de novo methyltransferases (DNMT1, DNMT3A and DNMT3B). The levels and 
patterns of DNA methylation are regulated by both DNMT and others molecules that 
cooperate in cytosine demethylation, like the ten-eleven translocation (TET) family of 
dioxygenases (TET1, TET2 and TET3). The functional outputs of DNA methylation on 
chromatin and gene expression are due to specific protein ‘reader’, for example Methyl-
CpG-binding domain (MBD). In this context the TET protein catalyze iterative oxidation on 
5mc resulting in the formation of 5-hydroxymethylcytosine (5hmc), 5-formylcytosine (5fc) 
and 5-carboxylcytosine (5caC). 
Taken together all these phenomena, histones and DNA together with all the modifications 
they are subjected to, work in a cooperative manner in a way that enable the chromatin to 
answer to environment, stimuli or stress through rapid changes in its organization in order 
to recruit or viceversa to remove specific effector proteins all along the entire genome. 
1.1.4. Post-translational modifications 
Among the most studied and well known PTMs, there are acetylation and methylation 
occurring on histone lysine residues, phosphorylation of serine, threonine and tyrosine, 
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ubiquitylation of lysine [33]. Other histone PTMs such as crotonilation, lysine butyrylation, 
lysine propionylation are less abundant (Table 1).  
There are several complexes responsible for the deposition of these modifications (Table2). 
For example the so-called histone acetyl transferases (or HATs) are the ones capable of exert 
the acetylation of lysines using acetyl-CoA as cofactor to catalyze the transfer of an acetyl 
group to the Ɛ-amino group of lysine lateral chain. Several proteins belong to this group: 
CBP/p300, MYST and GNAT families. Acetylation neutralizes the positive charge of 
lysines, thus weakening interactions between histone and DNA, leading to an increased 
accessibility of DNA to the transcription machinery. Indeed, they are found to be enriched 
at actively transcribed regions. Histone acetylation has been demonstrated to be also 
important during DNA replication and be indispensable for origin firing [34, 35]. Moreover, 
acetylated lysines can be recognized by bromodomains of chromatin remodeler proteins, 
thus influencing the chromatin structure [35] High throughput approaches revealed that 
H3K27ac was enriched at promoter regions of transcriptionally active genes [36], but also 
Polycomb target sites. Indeed, H3K27ac has dynamic and complementary temporal 
deposition profiles during embryogenesis [37]. This is a highly dynamic modification since 
once added it can be removed by specific erasers called histone deacetylases (HDAC). 
Also histone phosphorylation is highly dynamic. It takes place on serines, threonines and 
tyrosines, predominantly [38]. Its balance is controlled by two functionally opposite 
molecules that are kinases and phosphatases which respectively add and remove the 
modification [39]. The kinases act transferring phosphate group from ATP to the hydroxyl 
group of the target amino-acid side chain. When this modification is added to the histones, 
the final outcome is that they resulted characterized by an increased amount of negative 
charge, which in the end will affect the chromatin structure.  
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Table 1: Summary of residues subjected to post-translational modification and their functional outcome. 
From Kouzarides 2007 [40].  
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Table 2: List of enzymes that induce epigenetic modifications 
Adapted from Kouzarides 2007 [40]. 
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1.1.5. Histone methylation 
Histone methylation is a PTM that can occur on all basic aminoacidic residues such as 
arginines, histidines and lysines. It is possible to find monomethylated and symmetrically- 
or asymmetrically dimethylated arginines on their guanidinyl group. Histidines can be 
monomethylated. Lysines can be mono (me1)-, di (me2)- and tri-methylated (me3) on their 
Ɛ-group. Mass spectrometry and quantitative proteomic analyses [41] revealed that histone 
H3 has several basic residues that can be modified. In particular the best characterized 
arginine (R) sites that can be methylated include H3R2, H3R8, H3R17, H3R26 and H4R3. 
Instead, for lysines the most well-known and characterized sites are histone H3 lysine 4 
(H3K4), H3K9, H3K27, H3K36, H3K79 and H4K20. 
Compared to others PTMs, histone methyl groups are characterized by a slower turn over. 
Indeed this modification has been thought to be irreversible [42] until 2004 when Shi and 
colleagues reported firstly evidence of the existence of an “histone lysine demethylase”, 
specifically lysine-specific demethylase 1A, KDM1A (or LSD1) [43]. Thereafter, a plethora 
of methyltransferases and demethylases have been discovered. These enzymes mediate the 
addition to, and removal of methyl groups from the lysine residues on histones [44]. It is 
also true that the lower or greater duration of the presence of the modification rely on the 
specificity of the ongoing process. 
Methylated histones are recognized by the “readers” that mediate the recruitment of other 
molecules to alter chromatin structure and consequently transcription [45]. Indeed histone 
lysine methylation can promote both active transcription, such as in the case of the tri-
methylation (me3) of H3K36 and H3K4, or transcriptional repression, as in case of 
H3K9me3 and H3K27me3. In this sense, the methylation mark can be suitable for dynamic 
regulation of gene expression, since it can be actively added and removed from histone tails. 
The enzymes responsible for the histone methylation on lysine residues are the histone lysine 
methyltransferases (HKMTs).  They use S-adenylmethionine (SAM) to add methyl groups 
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to their specific substrate.  
The HKMTs can be divided in two different families based on the characteristics of their 
catalytic domain. The first class is characterized by a SET domain. This is an evolutionary 
conserved sequence motif of 130 amino acids which was initially identified in Drosophila 
position-effect-variegation (PEV) suppressor gene Su(Var)3-9, in the Polycomb group (Pc-
G) gene Enhancer of Zeste (E[z]) and in the activating Thritorax group (Trx-G) gene 
Thritorax [46]. It performs the transfer of a methyl group from S-adenosylmethionine 
(SAM) to the ɛ-amino group of the lysine (Fig. 1). The second family consists only in a 
single protein, Dot1L that is devoid of a SET domain [47].  
 
 
Figure 1: Mechanism of methylation. 
The lysine amino group of the substrate histone polypeptide starts a reaction with the activated co-factor S-
adenosylmethionine (SAM), resulting in the formation of an N-methylated lysine and S-adenosylhomocysteine 
(SAH). Adapted from Helin and Dhanak 2013 [48]. 
 
HKMTs retain high specificity for the substrate and some of them are even specific for a 
given methylation state. Indeed, inside the SET catalytic pocket domain an aromatic residue 
(a tyrosine or a phenylalanine) can play an essential role in controlling the state of 
methylation [49]. Taking into consideration their role in regulating transcription, among the 
most relevant lysine methylations, there are H3K4me1, H3K4me3 H3K9me3 and 
H3K27me. The latter PTM is deposited by Polycomb Repressive Complex2 (PRC2). 
The first methyltransferase identified as able to selectively regulate H3K9 methylation was 
Suv39H1/2 [50], which deposits H3K9me3 mark. Subsequently, it was reported that the 
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H3K9 mono- and dimethylation is controlled by the G9a enzyme [51] and its paralogue Glp 
[52]. Suv39H1 acts preferentially on mono- or dimethylated H3K9 as a primary substrate 
[51]. The trimethylation of H3K9 and the subsequent binding of heterochromatin protein 1 
(HP1) mediate the formation and maintenance of pericentromeric heterochromatin. Indeed 
during the mitosis numerous SUV39H1 factors are transiently accumulated at 
pericentromeric heterochromatin, suggesting that this KHMT may also play a structural role 
in these regions [53].   
The first and unique enzyme identified in S.cerevisiae containing a SET domain able to 
specifically methylate lysine 4 on histone H3, a mark associated with transcriptionally active 
chromatin, was Set1 [54]. In mammals, instead, about ten enzymes exist which can contain 
a SET domain related to yeast Set1 or to Drosophila Trithorax. Together they are classified 
as MLL family, which includes six members. The presence of a number of H3K4 
methyltransferases raises the question of why yeast can satisfy the task with just one enzyme 
while in mammals multiple isoforms are required [55]. It has also been shown that mutations 
occurring in different MLL genes are linked to different phenotypes. This suggest that these 
proteins are likely to be not fully redundant in their functions, but that they are all necessary 
in order to accomplish the complexity of the developmental process in mammals [56-58]. 
The MLL methyltranferases exist in a multiprotein complex with other subunits whose 
composition is highly similar to the Set1 complex in yeast [59]. Despite their association 
with several different subunits, a constant core made of three factors exists: WDR5, which 
interact with the histone H3 tail [60], presenting the chain to the other two proteins, RbPB5 
and Ash2, that further methylate it [61]. The MLL family can form a complex with other 
partners like Menin, which is required for maintenance of Hox gene expression [59] or HCF-
1, a regulator of cell proliferation involved in both cell growth and division processes [62].  
MLL complex has the important role of antagonizing the repressive activity of Polycomb 
complexes by depositing methylation on H3K4 [63]. Indeed, in vitro studies demonstrated 
that when MLL proteins catalyze H3K4 trimethylation it impairs Polycomb activity in 
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depositing the H3K27me3 mark [64]. Several promoters of eukaryotic genes are 
characterized by the presence of H3K4me3. This modification is able to recruit nucleosome 
remodeling complexes and acetyltranferases [65, 66]. This results in the transcriptional 
activation of these promoters. Moreover, these sites have been found also enriched for RNA 
polymerase II [67].  
In mouse embryonic stem cells there are several so-called bivalent promoters. The term 
“bivalent” is due to their contemporary features of both active and repressive chromatin 
since they are characterized by the presence of the two functionally opposite histone marks 
H3K4me3 and H3K27me3 [68]. A large proportion of these kind of loci corresponds to 
developmental genes encoding transcription factors and other regulators of the cellular state. 
These genes are mostly repressed in pluripotent cells but they can be rapidly turned on or 
stably inactivated according on the developmental stage that it is necessary to achieve or 
maintain. 
Another important regulatory DNA region that is regulated by PTMs is represented by 
enhancers. The activation of these regions is able to greatly increase the transcription of gene 
promoters. Moreover these loci can regulate genes whose distance can range from hundreds 
of bases to megabases [69]. These regions are characterized by the deposition of several 
PTMs [70, 71], the most common of which is H3K4me1 [72, 73]. Besides this modification 
they can accommodate H3K27 acetylation. If they are marked by both of these modifications 
they are called active enhancers, while in the absence of the histone acetylation and/or 
presence of H3K27me3 they are called poised enhancers [74, 75].  
Another important epigenetic mark linked to active transcription is H3K36me3. This 
modification is present all along the gene bodies. There are several enzymes responsible of 
this modification, such as Ash1L, NSD1, NSD2, NSD3 and Setd2 [76].  
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1.2 Polycomb group of proteins and their role on 
chromatin 
1.2.1 Overview of Polycomb proteins 
Polycomb group of proteins (PcG) were firstly described in Drosophila Melanogaster as 
master regulators of Hox genes, a set of transcription factors necessary for the correct 
establishment of proper segmentation along the anteroposterior axis of the body [77, 78]. In 
particular during D. Melanogaster embryonic development, PcG proteins regulate timing 
and spatial expression of the homeobox genes of the Hox cluster, thereby determining the 
proper activation of homeotic genes [79].  
In particular PcG proteins ensure that Hox genes are kept silent outside of their expression 
domains, whereas another group of proteins, the Trithorax group (trxG), exert the opposite 
functional role to maintain these genes actively transcribed in their appropriate domains in 
accordance to a precise developmental timing [79]. In Drosophila, Hox genes are active 
during early embryogenesis and are maintained silenced during adult life via epigenetic 
mechanisms. The regulation of these genes is very important and continues along all the life-
span of an organism. Indeed several lines of evidence highlighted that mutations in the Hox 
genes are linked to several developmental disorders and different kind of cancers. The Hox 
genes on one hand and the function of PcG and TrxG proteins on the other, as regulators of 
developmental genes, are strongly conserved in mammals [80].  
The first homolog of PcG found in mammals was Bmi1, Psc in Drosophila, for its 
cooperation in Myc-induced lymphomagenesis [81, 82]. Other mammalian homologs were 
unraveled in 1997 thanks to functional analyses on murine genes [83]. Functional and 
biochemical studies showed that these proteins are present in all cell nuclei in mammals and, 
importantly, in the form of complexes.   
These complexes (and their cooperation with TrxG) play fundamental roles in order to assure 
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the correct embryogenesis, tissue differentiation [84, 85], X-chromosome inactivation [86] 
and regulation of imprinted genes [87-89]. PcG complexes are also associated with nuclear 
reprogramming and chromatin remodeling [90]. 
The PcG complexes were called Polycomb Repressive Complex 1 (PRC1) and Polycomb 
Repressive Complex 2 (PCR2). These macromolecular complexes contain several Polycomb 
factors having different and still not fully understood functions. From their discovery, they 
have been linked to transcriptional repression but growing evidences highlight their possible 
involvement in transcriptional activation [91, 92].  
PRC2 is able to deposit H3K27me1, H3K27me2 and H3K27me3 thanks to HKMT ability 
of its catalytic subunits Ezh1/Ezh2. These proteins are able to exert their functions through 
the cooperation with core and accessory proteins that together constitute the PRC2 complex.       
PRC1 is larger and more diversified with respect to the first complex, and is responsible for 
the deposition of ubiquitylation on K119 of histone H2A (H2AK119ub). Both activities are 
linked to chromatin compaction and transcriptional repression. 
PcGs activity is regulated in a cell type-specific manner. Indeed, PcGs directly control the 
expression of cell-type specific gene-sets, contributing to the correct establishment of 
lineage-specific transcription programs [93]. 
The two PcG complexes share a large amount of common target genes, showed by a large 
number of chromatin immunoprecipitation (ChIP) experiments. This view has been recently 
challenged from different experiments coming from several laboratories which show that 
near the common sites there are other regions in which is possible to find only component 
of the PRC1 complex [94]. This became clearer with the discoveries of multiple possible 
PRC1 complexes.   
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1.2.2. Polycomb Repressive Complex 1 
Among PcG complexes PRC1 is larger and more heterogeneous. There are several 
biochemically distinct PRC1 subcomplexes [95, 96]. Each of these subcomplexes contains 
the PRC1 catalytic subunit RING1A or RING1B able to perform monoubiquitylation on 
lysine 119 on histone H2A (H2AK119ub). On the other hand, they differ one from another 
for the presence of one specific PCGF subunit. These latter subunits play an essential role 
since they are crucial for the functionality of RING1 ligases. Indeed, a possible classification 
in six PRC1 sub-complexes based on which PCGF protein is present has been proposed. 
Another possible classification is based on the presence in the sub-complex of Polycomb 
Chromobox homolog (CBX) or Rybp/YAF2 factors. According to this classification, PRC1 
complexes can be distinct in canonical and non-canonical.  Canonical PRC1 are the ones 
containing CBX proteins able to recognize the H3K27me3 deposited by PRC2. Another 
important subunit necessary for the correct organization of this kind of complex and for the 
activity of RING1 is BMI1 (PCGF4). It can be substituted by Mel18 (PCGF2) even if in 
vitro this last subunit showed no ability to enhance PRC1 activity [97]. So there are the so-
defined PRC1-PCGF2/4CBX subcomplexes [92] or PRC1.2 and PRC1.4 [95] (Fig. 2). These 
complexes agree with the general view of PcG recruitment. PRC1 is recruited to specific 
chromatin loci through the action of CBX proteins that recognize the H3K27me3 histone 
mark established by PRC2. This has been pointed out by studies in which the depletion of 
PRC2 was able to induce a loss of Ring1b at specific common target sites [98]. 
On the other hand there are other PRC1 target loci where Ring1b and its mark are present 
despite PRC2 absence. These regions are the ones characterized by the presence of the so-
named non-canonical PRC1. These other sub-complexes contain RYBP and its paralogue 
YAF2 instead of CBX proteins and can contain PCGF1, PCGF2 or PCGF4, PCGF3 or 
PCGF5, PCGF6 together with other subunits [95].  
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Figure 2: Biochemistry of the different PRC1 complexes. 
The assigned nomenclature is from the original publication by Gao et al.  giving that specific PCGF proteins 
associate with either CBXs or RYBP/YAF2, defining the functional and biochemical nature of the complexes. 
Adapted from Scelfo et al. 2015 [92] 
 
RYBP and CBX-containing complexes share anyway a large amount of common targets 
genes [92, 99, 100]. More precisely, it seems that they bind the same sites in adjacent regions 
[95]. Moreover it has been shown that PRC1-PCGF2/4 complexes cannot deposit 
H2AK119ub if forcedly recruited on chromatin [94]. This can suggest that an already 
deposited H3K27me3 can be crucial to assure PRC1-PCGF2/4 activity and that the 
deposition of the H2AK119ub is largely dependent on the activity of RYBP/YAF2-
containing complexes. The ways through which the PRC1 and the specific sub-complexes 
localize on specific regions on the chromatin still remain an open question. In this context a 
novel study uncovered a role for Kdm2b in recruiting PRC1 on chromatin [101]. Kdm2b, is 
a histone H3K36me3/2 demethylase mainly present in the complex PRC1-PCGF1, which is 
responsible for the large amount of H2AK119ub present in mESCs [95]. It contains a CXXC 
domain that has a high affinity towards CpG-rich DNA regions, in line with its localization 
to CpG-rich promoters [102]. Moreover Kdm2b depletion in mESCs leads to premature 
differentiation [103] similarly to what happens after Ring1a/b loss of function [104]. Also 
the non-canonical PRC1-PCGF6 has been showed to have a fundamental role in regulating 
ESC identity [95, 105]. Indeed it has been demonstrated that loss of subunits, L3mbtl2 and 
Wdr5 in particular, belonging to this complex, cause mESC premature differentiation [106, 
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107]. However, PRC1-PCGF6 is formed by subunits that are shared with independent 
complexes. Indeed, Wdr5 is also an essential protein of all COMPASS complexes that 
control all H3K4 methylation states [108]; Max is the well-known partner of Myc [109]; 
E2f6, can also associate with members of PRC2 and G9a/GLP complexes during 
proliferation [110, 111]; Hdac1/2 are partners of several different repressive complexes 
[112]; L3mbtl2 is found present also in the NuRD complex [107]. Why these proteins are 
incorporated in this PRC1 sub-complex and their role remain poorly characterized. For 
example it has been shown is that even if L3mbtl2-PRC1 complex can perform the 
deposition of H2AK119ubq on recombinant nucleosomes [105], in mESCs the ablation of 
L3mbtl2 cause no change in the levels of this modification [107], thus possibly suggesting a 
specificity in the mark deposition for L3mbtl2. The PRC1.3/5 and are even more poorly 
characterized. What has been observed is that forcing the recruitment of Pcgf3 and Pcgf5 on 
the chromatin, this induces the deposition of the modification and PRC2 recruitment [94]. It 
is overall clear that what is known regarding molecular and biological roles of all these PRC1 
sub-complexes is still poor and largely not understood.  
 
1.2.3. Polycomb Repressive Complex 2 
Polycomb Repressive Complex 2 is smaller than the other PcG complex and less diversified.  
This complex is composed of factors maintained conserved from Drosophila to mammals. 
The core subunits are suppressor of zeste 12 (Suz12), embryonic ectoderm development 
(Eed), Retinoblastoma associated protein 46/48 (RbAp46/48) and enhancer of zeste 
homolog (Ezh1 and Ezh2) which represent the catalytic subunits of the complex (Fig. 3). 
Ezh1/2 are in fact characterized by the SET domain responsible for lysine-methyltransferase 
activity. The two Ezh1 and Ezh2 proteins can exert the same activity but they are present 
with cell type specific expression pattern and they have different capabilities in binding 
chromatin. Each of the core proteins is crucial for the correct activity of the complex both in 
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vivo and in vitro [97, 113] and necessary for the correct development of an organism. Indeed 
it has been demonstrated that mice depleted of Eed, Suz12 and Ezh2 die at early embryo 
stage [114, 115].  
 
 
Figure 3: Principal members of PRC2 complex. 
The illustration depicts the core members of PRC2, with other proteins and relative binding properties. Adapted 
from Margueron and Reinberg 2011 [116].  
 
Others non-core proteins are PCL1/2/3, AEBP2, Jarid2. They can increase PRC2 binding, 
chromatin targeting and PRC2 activity [117].  
PRC2 is able to perform mono-, di- and tri-methylation states on H3K27 (H3K27me1, 
H3K27me2 and H3K27me3). These modifications can be deposited in a stepwise manner 
going from the mono- to di-methylated, until the trimethylation of H3K27. 
Studies in vitro analyzing the Km of these reactions showed that the preferential substrates 
for PRC2 are most H3K27me0 and H3K27me1 with respect to H3K27me2 [118]. PRC2 is 
able to achieve different regulatory outcomes across different developmental stages and cell 
types thanks to the cooperation of accessory proteins. AEBP2 [97] is able to enhance PRC2 
activity and colocalize with PcG targets. Also PCL, Polycomb-like Proteins (Pcl1-3)[119, 
120], MTF2 [121, 122], PHF19 [123] are tissue specific and interact with EZH2. They are 
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characterized by a PHD tudor domain able to recognize the active H3K36me3 mark, possibly 
suggesting a function in silencing active genes [124].  
Fundamental factors for Polycomb activity are represented by Jumonji and ARID containing 
protein Jarid2 found in association with Ezh2 [125, 126]. Jarid2 is important for the 
establishment of the correct development of mESC and its loss impairs the ability of PRC2 
to localize to its specific target genes. Nevertheless, the link between Jarid2 and the 
H3K27me3 deposition is still controversial. In fact while some authors showed a reduction 
of this mark upon Jarid2 depletion [125, 127], others found no change nor enhanced mark 
amount [126, 128]. Since PCL and Jarid2 are mutually exclusive in the binding to the 
complex it is thought that they can be responsible for the specific targeting of PRC2 to 
certain genes [124]. 
PRC2 is responsible for the methylation of about 80% of bulk histone H3 in mESC. Our 
laboratory has demonstrated that each modification deposited by PRC2 is present in specific 
loci that are spatially mutually exclusive in mESC [129].  
In more detail, we showed that H3K27me1 is localized in the gene bodies of actively 
transcribed genes where it is found in co-presence also of another transcriptionally active 
mark, H3K36me3, facilitating the active transcription; H3K27me2 is deposited in intergenic 
regions, spread in the genome where it exerts protective function preventing firing of non-
cell type specific enhancers while H3K27me3 is present on promoters where it exerts 
repressive regulation of specific target promoters [129].    
 
1.2.4. Polycomb recruitment to target loci 
In Drosophila, PcG complexes are able to interact with chromatin through cis-elements 
known as “Polycomb response elements” (PREs) [130, 131]. There are numerous PRE in 
Drosophila genome [132-134] and genome-wide studies showed that PREs are described as 
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binding sites for both PRC1 and PRC2 subunits but also for other transcriptional factors that 
can play a role for the PcG binding itself. These analyses allowed the development of an 
algorithm whose aim was to find eventual novel PREs showing that some predicted elements 
have PRE proprieties in vivo [131]. Despite this, genome wide experiments show a very 
scarce overlap between PcG binding sites and the predicted elements [135]. Indeed although 
lots of studies have been made to predict PREs computationally [131, 136], it still is not 
possible to predict sequence of DNA having a kind of PRE activity. 
Regarding PcG recruitment in mammals, since Drosophila DNA binding proteins resulted 
to be poorly conserved in mammalian cells, the application of such algorithm to mammalians 
genome fails to predict any potential PRE [131]. For example, in Drosophila PHO is one of 
the proteins that mediate the recruitment of PRC2 to chromatin. The mammalian homolog 
is Ying Yang 1 (YY1). Genome-wide analysis demonstrated that YY1 is not able at all to 
induce a recruitment of PRC2 in fact there are no correlations between the distribution of 
YY1 and PcGs. Moreover YY1 is devoid of any sequence known to be targeted by the PcGs. 
Consequently it has been demonstrated that YY1 exerts PcGs-indipendent functions in 
mESC [137]. 
For these reasons mechanisms by which PcG complexes are recruited to specific DNA sites 
are still poorly understood. Genome wide studies have shown that PcG proteins bind 
preferentially CG rich genomic regions. Nevertheless sequence analysis failed to identify 
consensus sequences [138] maybe also because PcG proteins can remain bound to their 
target loci for a very small time frame. Opposite to this, other works have identified 
mammalian genomic regions with putative PRE behavior [139] supporting a mechanistic 
conservation between flies and mammals.  
Moreover, it has been demonstrated that PcG and TrxG proteins seem to compete in 
metazoan for the same regulatory pathways and binding sites. Despite the mechanisms of 
recruitment are poorly understood, deregulation of such equilibrium by either loss or gain of 
function of specific subunits may result in changes in cell identity that in the end could play 
35 
 
essential roles in pathogenesis. For example it has been shown that also proteins of Trx 
complexes are able to bind CpGi depositing the functionally opposite mark, H3K4me3, 
through the association via Zn-Finger-CXXC domain of these proteins. In this way it is 
possible a competitive binding between Trx and PcG at the same target loci. 
Another factor that has been demonstrated to have a role not only at the PRC2 functional 
level but also for its targeting in mouse ES cells to chromatin is Jarid2 [125]. Despite Jarid2 
interaction to PRC2 is not restricted to ES cells, the differences in target genes between cell 
types suggests tissue specific mechanisms of PcG recruitment [115, 140]. It has been also 
demonstrated that in absence of prior H3K27me3, PRC2 can be recruited by Jarid2 only if 
this protein has been previously methylated on its K116 by PRC2 itself.  
It has been speculated that pre-existing H3K27me3 is necessary for the maintenance of the 
mark during replication but the deposition of the mark on new domains during differentiation 
require methylated Jarid2.    
Apart from Jarid2, there are other factors that are able to localize PcGs to specific regions 
on the chromatin. Regarding PRC1, it has been shown that transcription factor REST is able 
to interact with CBX proteins inducing the recruitment of the complex independently of the 
PRC2-deposited mark and of unmethylated CpGi. Moreover Bmi1 has been purified with 
Runx1/Cbfβ that in turn is able to recruit PRC1 in a PRC2-independent manner. For what 
concerns PRC2, it has been shown that REST [141], Snail1 [142], PML-RARα [143], PLZF-
RARα [144] can physically interact also with this complex. Besides these mechanisms, 
biochemical interaction studies showed the association of PcGs with long non coding RNA 
promoting Xist-mediated X-chromosome inactivation [145].  
For what concerns the general view, the accepted model is based on the hierarchical 
recruitment PRC1-PRC2 dependent mechanism [101]. In this view PRC2 is targeted to 
specific target loci; once there it deposits the H3K27me3 mark that in turn recruit PRC1 
because the chromodomain of its CBX proteins are able to bind the mark. This idea came 
from experiments showing that stable components of PRC1 like the CBX proteins can target 
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the entire PRC1 directly to chromatin through their ability to bind the H3K27me3 mark 
[146]. In support of this model, there are genome wide studies that identified subunits of 
both the complexes occupying the same regions rich in CGs [114, 146, 147]. 
On the other hand, the discovery of non-canonical PRC1 and more detailed studies on the 
PRC2 lead to the discovery of novel mechanisms of recruitment that continuously 
challenged the classical hierarchical one. In support of this new viewpoint it has been 
demonstrated that in ESCs not every region is co-occupied by both the complexes. In 
particular, 25% of regions were occupied by Eed and Suz12, components of PRC2 together 
with PRC1 subunits Phc1 and Ring1b [114]. A more recent work found that around 90% of 
sites occupied by Ring1b were also bound by Ezh2 and that just 50% of sites occupied by 
the latter subunit were also bound by Ring1b [148]. Moreover several groups made 
observations supporting the non-classical hierarchical model. Indeed it has been found that 
some loci are characterized by the presence of PRC1 and relative mark also in absence of 
PRC2 [98, 149, 150]. In addition Blackledge and colleagues showed that indeed it was 
possible to observe an opposite way of recruitment for the two complexes. In fact they 
demonstrated that variant PRC1 once occupied some loci, are able to induce the recruitment 
of PRC2. In this experiment they observed a PRC1-dependent PRC2 and H3K27me 
deposition. In particular they showed that PRC1 complexes containing Pcgf1, Pcgf3 and 
Pcgf5 after being forcedly recruited to chromatin, are able to greatly deposit H2AK119ub1 
with subsequent nucleation of PRC2 complex which then, in turn deposits H3K27me3.   
Concomitantly, in the case of PRC1 catalytic portion depletion in mESC, they observed a 
strong decrease in PRC2 deposition. It has also been previously observed that ESCs depleted 
of PRC2 do not undergo a change in the levels of the H2AK119ub. In particular it has been 
demonstrated that the abrogation of the entire H3K27me3 in Eed null mouse ES cells affects 
global Ring1b stability at chromatin but this does not affect the histone H2A lysine 119 
mono-ubiquitination (H2AK119ub) levels [98]. These data indicate that, although PRC2 
activity is required to stably localize the PRC1 at chromatin, H3K27me3 is generally 
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indispensable to maintain the global H2AK119ub levels. Moreover, the non-canonical 
PRC1.1 complex containing Pcgf1, Rybp, Bcor and the demethylase Kdm2b, is recruited to 
chromatin thanks to the Kdm2b domain that confers the affinity for CpGi. Indeed the 
demethylase is found associated to almost all CpGi (also to those that are non-PcG targets) 
to both active and bivalent genes that can become targeted during differentiation.  
Finally, in a study the authors through an affinity purification assay using nuclear extract 
from mouse ESCs and Drosophila embryos showed that PRC2 results more able to bind 
nucleosomes harboring H2A when modified as H2AK119ub [151]. 
In conclusion, the recruitment models are more likely not mutually exclusive, acting in cell 
type specific manner and in synergy to help in addressing proper target modification during 
differentiation.  
 
1.3. Epigenetics and diseases  
Great advances in knowledge and technology allowed reaching extensive comprehension of 
the epigenetics and of its relevance. Many studies demonstrated the strict correlation 
between dysregulation of epigenetics-related factors and the onset of different kinds of 
diseases. In this context, lots of effort demonstrated a correlation between epigenetics and 
neurological disorders, autoimmune diseases and cancers. 
Regarding neurological disorders it has been reported that many of these diseases are 
characterized by both hypo- and hyper-methylation of DNA. For example, patients affected 
by Parkinsons’s disease overexpress TNFα because of a hypo-methylation of its promoter. 
Other diseases have been linked to the altered deposition of histone modifications, such as 
histone hypoacetylation in amyotrophic lateral sclerosis (ALS) patients. These patients are 
characterized by aggregates of the FUS protein in deposits of misfolded proteins in the 
cytoplasm. Since FUS factor is able to inhibit CBP binding it, it is responsible of the negative 
regulation of CREB targets [152, 153]. In this context, high amounts of FUS proteins lead 
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to histone hypoacetylation. Others examples are Huntington’s disease and Friedreich’s 
ataxia in which it is possible to observe a hypertrimethylation of H3K9 [154].  
For what concerns autoimmune diseases, one of the best characterized is the 
immunodeficiency, centromeric instability and facial abnormalities (ICF) syndrome that is 
due to a heterozygous mutation occurring on DNMT3B [155, 156]. The effect of this 
mutation is that some DNA regions are found hypo-methylated. Another example is 
represented by systemic lupus erythematosus in which a correlation has been found between 
the disease and the alteration in the DNA methylation (hypomethylation) and histone 
deacetylases [157].  
 
1.3.1 Epigenetics and cancers 
Cancer is a heterogeneous disease that involves at the molecular level a multitude of different 
regulatory pathways and proteins. In general, at malignant stages, cancer cells acquire 
unlimited replicative potential, angiogenesis capabilities, the ability to evade apoptosis, self-
sufficiency in growth signals, insensitivity to growth inhibition and invasive (metastatic) 
properties [158]. To achieve this, cells undergo a multistep process which gradually leads to 
the loss of cellular identity towards the acquisition of cancer cell capabilities. In both 
sporadic and hereditary cancers a large number of genetic alterations have been 
characterized. Such genetic mutations are required but not fully sufficient for cancer 
development. Indeed tumors undergo a latency period before the onset of the disease in order 
to accumulate additional genetic or epigenetic alterations to allow full cancer development 
[159].  
Lots of evidences and observations have linked strictly the role of epigenetics to the 
development of cancer (Table 3). In particular it became gradually more evident that 
tumorigenesis can be linked to the distortion of epigenetic programs [160]. These alterations 
could lead to changes in the genetic expression patterns, with activation of oncogenes [161] 
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or silencing of tumor suppressor genes [162]. In this sense, epigenetic dysregulation can lead 
to the tumorigenesis. However, since the epigenetic regulatory machinery is reversible and 
dynamic, it possesses the potential to either cause or cure diseases, especially cancer itself. 
For these reasons lots of efforts are being exerted trying to dissect the role of epigenetics and 
key factors involved in the reversion of the epigenetic programs linked to tumorigenesis 
development to those typical of the normal condition. This makes epigenetics very 
promising for the development of new drugs in the future.  
 
 
Table 3: Epigenetic regulators altered in cancer. 
Adapted from Muntean and Hess 2009 [163].   
 
1.3.1.1 DNA methylation  
Regarding methylation, cancer cells can be characterized both by hyper and 
hypomethylation of DNA. In particular, a normal cell present overall genome-wide 
methylation with the exception of CpG islands, which are found unmethylated [164]. These 
methylation marks can affect the ability of certain transcriptional factors to bind specific 
target sites and, in the end, the transcriptional rate. Furthermore the methylation sites could 
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work as docking regions for methylated DNA binding proteins (MBD1, MBD2, MBD3, and 
Mecp2) that in turn could be bound by other histone modifying enzymes like histone 
deacetylases (HDACs). This can result in activating or repressing transcription [165].  
In tumor cells an overall loss of methylation can lead to the hypomethylation of entire 
genome with the exception of CpG island promoters, which in contrast undergo 
hypermethylation [164]. 
In a normal cell DNA methylation is commonly present at telomeres, centromeres, inactive 
X-chromosome and at repeated sequences. It is therefore clear that the presence of 
hypomethylation observed in cancer cells has been linked to an increase in genomic 
instability inducing chromosomal rearrangements [166]. But this can also cause a 
reactivation of retrotransposons which translocate to other genomic regions, contributing to 
the propagation of genomic instability [167]. Another example is the hypomethylation of 
growth-promoting genes induces their activation. This is the case of Ras and of mammary 
serine protease inhibitor (MASPIN) for gastric carcinoma [168]. Moreover, 
hypomethylation can cause loss of imprinting, which is what happens to insulin like growth 
factor 2 (IGF-2) as seen in Wilms' tumor [169] and colorectal cancer [170]. 
Regarding the hypermethylation, it has been demonstrated that it spreads all along CpGi that 
are present at the promoter region. CpGi hypermethylation can induce tumorigenesis by 
shutting down the expression of tumor suppressor genes. This can be achieved by direct 
action over tumor suppressor genes but also through indirect silencing. One of the first 
studies regarding the direct association between hypermethylation and repression of tumor-
suppressor genes identified that the hypermethylation of Rb promoter gene at its CpGi 
(retinoblastoma associated tumor suppressor gene) was able to promote retinoblastoma 
malignancy. p16 and BRCA1 are other tumor suppressor genes silenced trough the 
hypermethylation of their promoters [171]. Since these genes are very important for cell 
adhesion, apoptosis, and angiogenesis, their silencing facilitates the process of 
tumorigenesis. On the other hand, it is possible to observe an indirect function of CpG 
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promoter hypermethylation in silencing tumor suppressor genes. This is the case of several 
genes, such as RUNX3, GATA-4, and GATA-5 responsible respectively for esophageal, 
colorectal, and gastric cancers, whose silencing is responsible for the downstream target 
inactivation of the tumor suppressor genes, resulting in the propagation of cancer cells [162, 
172] 
 
1.3.1.2 Histone modifications  
On the other hand, also the histone PTMs play a role in inducing the disruption of the 
epigenetic programs occurring during onset and development of cancers. In particular 
acetylation and methylation have been strongly associated with cancer [173]. 
 
1.3.1.2.1 Histone acetylation and cancer 
The acetylation status of histones H3 and H4 is largely responsible for the fate of almost all 
the DNA-based processes such as chromatin assembly, transcription, and gene expression 
[174].   
Deregulation of HAT activity has been reported in both hematological and solid cancers. 
Generally these alterations cause the inactivation of HAT activity either through gene 
mutation or by the activity of viral oncoproteins. Regarding the latter case for example, the 
adenovirus E1A and SV40 T antigen proteins are able to bind p300/CBP [175] wherefore it 
has been shown to play an important role leading to cellular transformation [176]. The 
underlying mechanism involves the binding of these viral proteins to p300 and CBP that 
induces a reduction in the acetylation of H3 lysine 18 (H3K18) [177] with subsequent 
relocalization of these HATs to the promoter regions of a limited number of genes that 
promote cell growth and division, favouring their expression [178]. Also chromosomal 
translocations involving HATs have been related to the onset and progression of acute 
leukemia [179]. For example this happens in the case of acute myeloid leukemia (AML) and 
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acute lymphoblastic leukemia (ALL), in which the translocation leads to the production of 
the fusion protein MLL-CBP. MLL can also be aberrantly fused to p300 in AML through 
the t(11;22)(q23;p13) translocation [180].  
 
1.3.1.2.2 Histone deacetylation and cancer 
The principal role of HDACs is to oppose the activity of HATs and regulate transcription 
through the removal of acetyl groups from lysine present on histone tails and also from non-
histone substrates [181]. These enzymes are characterized by activities whose final effects 
can be different depending on the context and the cell type in which these activities are 
exerted. In general, while class I HDACs are mainly involved in cell proliferation and 
apoptosis, the class II HDACs are responsible for the regulation of cell migration and 
angiogenesis [182]. It is therefore clear that their deregulation can affect pathways that in 
the end can have a role in the onset or progression of cancers. Indeed, it has been shown that 
in an in vitro model of colon carcinoma, the knockdown of HDAC2 and HDAC1 is able to 
suppress the proliferation of these cells [183]. Moreover, knockdown of HDAC3 and 
HDAC2 induces DNA damage and concomitant apoptosis [184].  
Class II and IV HDACs are found predominantly in the cytoplasm and may preferentially 
deacetylate non-histone proteins [181]. It has been shown that decreasing the expression of 
HDAC4 causes cell proliferation inhibition and induction of apoptosis [168]. And the 
knockdown of HDAC6 and HDAC10 was shown to be able to cause the depletion of 
VEGFR1 and VEGFR2, growth factor receptors implicated in angiogenesis [185]. 
Deregulation of HDAC activity by chromosomal translocations has been strongly implicated 
in aberrant gene silencing and the promotion of tumorigenesis. This is true for leukemias. 
For example, acute promyelocytic leukemia (APL) represents one of the most well-known 
connections between tumorigenesis and aberrant HDAC activity. The retinoic acid receptor 
(RAR) is a transcriptional regulator involved in myeloid differentiation through the binding 
to its heterodimerization partner RXR, which in turn binds to retinoic acid response elements 
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(RAREs) within the promoters of target genes [181]. In APL, the chromosomal 
translocations t(15;17) and t(11;17) result in production of fusion proteins RARα-PML 
(promyelocytic leukemia protein) and RARα-PLZF (promyelocytic zinc finger), 
respectively. These aberrant proteins maintain the ability to bind RAREs and HDACs with 
high affinity independently from the presence of retinoic acid. This aberrant process 
derepresses RAR-targeted genes and prevents cell differentiation [186]. Also some kinds of 
non-Hodgkin's lymphomas characterized by abnormal expression of the Bcl-6 display an 
irregular recruitment of HDACs. In this way, genes important for assuring cell cycle arrest 
and apoptosis are silenced [182, 187]. Also altered expression of individual HDACs in 
various types of tumor samples has been reported. For example, HDAC1 is overexpressed 
in prostate, gastric, colon, and breast carcinomas [188, 189]. HDAC2 is overexpressed in 
colorectal [190], cervical [191], and gastric cancer, whereas overexpression of HDAC6 is 
observed in breast cancer [192, 193]. Finally also sirtuins can facilitate tumor onset and/or 
progression. Indeed they regulate transcriptional activity of important proteins such as p53, 
p73, pRb, NF-κB [194, 195]. 
 
1.3.1.2.3 Histone Methylation and Cancer 
With the advent of next generation sequencing at the chromatin and RNA level, the analysis 
of histone methylation marks showed that monomethylation of H3K27, H3K9, H4K20, 
H3K79, and H2BK5 is associated with gene activation, whereas trimethylation of H3K27, 
H3K9, and H3K79 is linked to gene repression. The subsequent binding of heterochromatin 
protein (HP1) to methylated H3K9, for example, promotes the formation of a transcriptional 
silent heterochromatin state through the association with DNMTs and HDACs [196]. It has 
been also demonstrated that mice in which HMT SUV39H has been knocked-out became 
more sensitive to tumorigenesis [197]. Several tumor cells have been reported to present an 
aberrant expression and deregulation of HMTs and demethylases, such as chromosomal 
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translocations involving MLL1, NSD1, NSD3, gene overexpression or amplification (i.e., 
EZH2, MLL2, NSD3, BMI1), gene silencing like RIZ1 and gene deletion MLL3 [192]. 
 
1.3.2 Polycomb and cancers 
The role of PcGs in cancer is currently one of the most interesting topics and a lot of effort 
is being invested to try to dissect its contribution to this disease [48, 198]. The biological 
role of these proteins is becoming more and more controversial [199, 200].  
The first evidence of a PcG protein having a direct role in cancer formation was the 
identification of BMI1 as a proto-oncogene that cooperate with MYC in the formation of B-
cell lymphomas [100]. Since then, the attention at role of PcG proteins in human cancer 
gradually increased. Together with BMI1, the best-characterized PcG protein in human 
cancer is the catalytic subunit of the PRC2 complex EZH2. This subunit was identified as a 
direct downstream target of the pRB/E2F pathway and has been shown to be the most 
frequent over-expressed gene in malignant prostate cancer [201]. Regarding the PRC1 
complexes, several and contradicting results have been presented, suggesting that the 
eventual PcGs oncogenic properties could be due to single subunits rather than the entire 
complexes. In addition few Polycomb proteins have been proposed as tumor suppressors in 
specific tumour types [202-204].  
To date it is difficult to interpret how PcGs can cause tumorigenesis in haematological 
malignancies [205, 206]. In fact, for example, loss of Eed in the adult haematopoietic 
compartment induces long-term HSC exhaustion and pancytopenia [207], while several 
papers highlighted the presence of inactivating mutations on PRC2 subunits connected to 
the onset of leukemia and myelodysplastic syndrome (MDS) [208, 209].  
Moreover, specific Ezh2 depletion in the haematopoietic system of adult mice is able to 
cause the onset of T-acute lymphoblastic leukaemias [204].  
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Furthermore it has been demonstrated the role of PRC2 activity in the development of MLL-
AF9 acute myeloid leukaemias (AML) [210]. Indeed while it has been shown that the 
depletion of PRC2 activity facilitate the onset of MDS and leukaemias induced by ASXL1 
mutations [211], it has also been reported that EZH2 loss can prevent the further 
development of MDS into AML [212]. 
More in general, it has been long proposed that the principal way through which PcGs favour 
tumour cell growth is due to their ability to repress the Ink4a/Arf locus, that negatively 
regulate the cell-cycle progression and for this reason it is a well-known non-cell-type 
specific tumour suppressor [213-215]. However, we demonstrated that mouse embryonic 
fibroblast genetically depleted of PRC1 or PRC2 activities became strongly affected in 
proliferation and transformation capabilities in an Ink4a/Arf-p53-pRb independent fashion 
[216]. Moreover we showed that PcGs can supervise and favour DNA replication by directly 
localizing at sites of ongoing DNA replication maybe being involved in the regulation of 
chromatin dynamics [216]. These observations pave the way to novel possibilities of treating 
cancer with EZH2 inhibitors despite the functionality of the pRb and p53 pathway, which is 
found very often inactivated in nearly all human tumours [217, 218]. 
 
1.3.2.1 Lymphoma and gain of function EZH2 mutations 
Among tumors molecularly characterized by mutations on PcGs, lymphomas seem to be the 
best candidates for PcG inhibiting compounds as they are characterized by a strong 
expression of PcG subunits and by high PcG activity [219].  
PcGs play important roles during germinal-center (GC) B-cell development. Indeed PRC2 
catalytic subunit EZH2 undergoes a very dynamic expression since it results massively 
upregulated during the rapid proliferation of B cells and immunoglobulin affinity maturation 
on immune activation, and subsequently decreased once these processes terminate [220, 
221]. This makes EZH2 a possible key factor in GC development.  
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EZH2 is expressed in a several B-cell neoplasms such as in Burkitt's lymphoma, mantle cell 
lymphomas (MCLs), follicular lymphoma (FL), and diffuse large B-cell lymphomas 
(DLBCLs) [222]. It is upregulated in MCLs as compared to the normal tissue from which 
the lymphoma originated [223]. Importantly the deregulation of EZH2 was linked to B-cell 
lymphomagenesis [222], correlating its expression levels with aggressiveness and 
unfavorable prognosis. 
Recent studies have tried to better understand the role of this subunit in these pathologies. 
Two groups [220, 224] have independently showed Ezh2 importance for GCs and GC B-
cell development using mice depleted for this gene. Indeed, EZH2 represses several genes 
including negative cell-cycle regulators and also key transcription factor IRF4 and 
BLIMP1/PRDM1 that are necessary for post GC B-cell development [224].  
In 2010 Morin and colleagues characterize firstly a heterozygous EZH2 missense mutations 
found in B-cell lymphomas of GC origin, such as DLBCLs and FLs [225]. These mutations 
are due to a single aminoacidic substitution specifically in the catalytic SET domain of the 
enzyme. The most common mutation is a point mutation on the Tyr641 residue (using a 
short isoform of the enzyme to count its amino acids) found mutated to either Asparagine 
(N), Phenylalanine (F), Cysteine (C), Serine (S), or Histidine (H) in about 7% of FLs and 
21% of DLBCLs [118, 225, 226]; two other rare EZH2 mutations, A677G and A687V , were 
reported in about 1%–3% of B-cell lymphoma cases [118, 225-227] and also in 2% of 
melanomas [228]. 
The first work that addressed the role of these particular EZH2 mutations considered them 
as loss of function variations, pointing at a role as tumor suppressor also in lymphomas 
[225]. Later studies demonstrated instead that they were acting as gain of function mutations, 
conferring an increased activity of the PcG complex towards the accumulation of 
H3K27me3 [229].  
Several papers after the first one have shown that lymphomas harboring these mutations 
induce an alteration in the substrate specificity of the complex [118, 229, 230] (Fig. 4). 
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Figure 4: Patterns of H3K27 methylation status in lymphoma cell lines harboring a WT of heterozygous 
mutant form of EZH2. 
Western blot analysis using the reported antibodies to unravel the  H3K27 methylation states for lymphoma 
cell lines containing homozygous WT EZH2 or heterozygous for the indicated EZH2 Y641 mutation. (Left to 
right) (From Sneeringer 2010 [229]). 
 
After the discovery of these mutations, kinetic studies tried to dissect the catalytic efficiency 
of the different complexes, the WT and the mutant ones, toward unmethylated (H3K27me0), 
mono-methylated (H3K27me1) and di-methylated (H3K27me2) substrates. These analyses 
showed that the WT complex can induce mono-, di-, and trimethylation of H3K27 but more 
in particular it exhibits the greatest catalytic efficiency in converting nonmethylated 
H3K27me0 to H3K27me1 and a lesser activity for subsequent (H3K27me1 to H3K27me2 
and H3K27me2 to H3K27me3) reactions [118, 229-231]. On the other hand they showed 
that mutant PRC2 complexes bearing these mutations, such as EZH2 harboring the mutation 
form tyrosine to asparagine ,Y641N, display very limited ability to methylate H3K27me0, 
but once H3K27 is monomethylated, they can catalyze the turnover of H3K27me1 to 
H3K27me2 and, then, much more rapidly convert the H3K27me2-to-H3K27me3 (Fig. 5).  
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Since the WT and mutant complexes are characterized by different enzymatic capabilities, 
in several paper it has been hypothesized that WT and mutant EZH2 could cooperate to 
produce the abnormally high level of H3K27me3 seen in the lymphoma cells [118, 229-
231].  
 
 
Figure 5: PRC2 complexes containing mutant EZH2 preferentially catalyze di- and trimethylation of 
histone H3K27. 
In vitro methyltransferase activity of mutant and WT complexes on unmethylated peptide (white bars), 
monomethylated peptide (grey bars), and dimethylated peptide (black bars) (From Sneeringer 2010 [229]). 
 
There are two other rare EZH2 SET domain mutations, A677G and A687V, that cause a 
change in the substrate specificity of PRC2 even if they are characterized by another 
different kinetic property [118, 226, 232, 233]. For example, the A677G is equally able to 
modify all the H3K27 substrates. On the other hand, the A687V mutation induces the 
formation of a complex able to methylate in the same manner H3K27me1 and H3K27me2 
but unable of methylating H3K27me0 [118, 226, 232, 233]. It is therefore clear that all these 
gain-of-function mutations in lymphomas induce PRC2 hyperactivity using different 
molecular mechanisms but anyway leading to the same outcome that is the globally elevated 
H3K27me3 phenotype characterizing lymphoma patient. Some papers more focused their 
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attention on the structure of the WT and mutants complexes trying to understand the 
substrate specificity using homology modeling [118, 230, 231, 234]. An important role is 
played by a hydrogen bond formed by the vicinity between ε-amino lysine nitrogen of the 
H3K27 and the oxygen of Y641 of the WT complex. This hydrogen bond is necessary in 
order to recruit H3K27me0 as substrate and furthermore to form a pocket able to include 
H3K27me2 and reducing its ability, rotating, to accept a third methyl group from the methyl 
donor. In case of mutant PRC2 complex containing the mutated form EZH2 Y641N, the 
presence of asparagine induces the formation of a smaller substrate-binding pocket. The final 
outcome is that H3K27me2 substrate is able to rotate more freely, which accelerates the 
transfer of an additional methyl group. Similar effects were observed for other EZH2 Y641 
mutations (Y641 to F, C, S, or H), but the most drastic effects were seen with EZH2 Y641N 
[118, 231, 235]. 
 
1.3.2.2 EZH2 as therapeutic target 
Taken together, all these evidences highlight a possible role of EZH2 enzymatic activity in 
driving tumorigenesis.  
For this reason several laboratories and pharmaceutical companies are investing to find novel 
promising compounds able to specifically inhibit EZH2 activity. Indeed preclinical results 
have been collected and human phase 1 trials is under investigation with very promising 
results. 
EZH2 inhibition has been pursued in two different ways. On one hand, the interference with 
the formation of PRC2 complex; on the other hand the direct targeting of its enzymatic 
activity. 
Regarding the first approach, that is the possibility to act preventing the formation of the 
PRC2 complex, a peptide called stabilized alpha-helix of EZH2 (SAH-EZH2) whose 
structure resembles the portion of EZH2 that interacts with EED [236] was developed. SAH-
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EZH2 in this way disrupts the EZH2-EED complex, can decrease EZH2 protein levels and 
consequently inhibits H3K27me3 in a dose-dependent fashion. This peptide has been 
demonstrated to be effective in both EZH2-mutant lymphoma cells and EZH2-dependent 
MLL-AF9 leukemia with no effect on nontransformed and EZH2–wild-type controls in 
vitro.  
Regarding the second approach, lots of compounds have been produced and analyzed. Firstly 
3-deazaneplanocin (DZNep) has been widely used in laboratories also in a human 
promyelocytic leukemia cell line [237]. This compound is able to repress the activity of 
SAM–dependent histone lysine methyltransferase activity by increasing the S-adenosyl-l-
homocysteine hydrolase (SAH). This means that even if DZNep induces significant 
antitumor activity in various tumor types [238], the induced impairment in histone 
methylation activity is not specific for EZH2, resulting in toxicity in animal models [239]. 
Subsequent studies have been aimed at developing compounds more specifically direct 
toward EZH2 activity. To achieve this purpose, several independent groups performed high-
throughput biochemical screens, obtaining different potent inhibitors such as EPZ005687, 
GSK126, EI1, UNC1999, EPZ-6438.  
EPZ005687 has been found able to bind to both WT and Y641mutant EZH2 showing 500-
fold selectivity for EZH2 compared to 15 other human methyltransferases and 50-fold over 
EZH1 [240]. EPZ005687 shows dose-dependent inhibition of H3K27me3 deposition in 
EZH2 WT and Y641. This molecule is able to inhibit also the A677-mutant EZH2 in 
lymphoma cells and also in cell lines of breast and prostate cancer.  
GSK126 showed to be even more specific, having 1000-fold greater selectivity with respect 
to other methyltransferases and 150-fold over EZH1 [231, 241]. In addition GSK126 
succeeded in impairing the growth of lymphomas in vivo [231]. Another promising 
compound, EI1, is able to bind both WT and mutant form of EZH2 showing selectivity over 
10,000-fold with respect to other methyltransferases and 90-fold over EZH1. It is able to 
affect both H3K27me2 and H3K27me3 and to impair the growth of cells harboring the 
51 
 
mutation but also to induce cell cycle arrest and apoptosis [242]. Many of the drugs described 
so far have to be frequently administrated. 
Another compound, UNC1999, demonstreated to be effective also against EZH1 (10-fold 
less with respect to EZH2), so it can be used to target EZH2 and EZH1 together.  
Finally a compound that entered a phase 1/2 clinical trials is EPZ-6438 to treat patients 
presenting B cell lymphomas or advanced solid tumors. It presents greater potency and better 
pharmacokinetics with respect to EPZ005687 [240]. 9 of 15 patients with Non-Hodgkin 
lymphoma and a patient presenting mutant EZH2 Y646H give back partial or complete 
responses when treated with this compound (as reported at the following link: 
http://www.epizyme.com/wp-content/uploads/2014/11/Ribrag-ENA-FINAL.pdf and 
http://www.epizyme.com/wp-content/uploads/2015/07/ICML-Slides-Presented-062015-
v2.pdf) [243].  
Taken together, these evidences show that compounds directed against EZH2 could be a 
promising tool for tumor targeting. In order to refine the design of new drugs for treatment 
of tumor-affected patients, it would be important to elucidate the mechanism of action 
through which the mutated form of EZH2 is able to contribute to tumorigenesis. 
 
1.4. Aim of the thesis 
My thesis is aimed at the dissection of the role of the mutated PRC2 catalytic subunit EZH2 
in the regulation of tumorigenesis. I focused my attention in particular on EZH2-Y641N that 
is one the most frequently mutations in a particular subset of diffuse large B cell lymphomas 
and follicular lymphomas. In particular we previously reported that EZH2 is responsible for 
the establishment of all the methylation states occurring on H3K27 (H3K27me1, 
H3K27me2, H3K27me3), each of them belonging to specific genomic domains and having 
specific roles [129]. My experimental hypothesis is that the mutated form of EZH2 can cause 
an alteration in the domains of deposition of these histone marks, possibly conferring an 
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oncogenic potential to cells. Here I show experiments aimed at shedding light on the 
molecular mechanism underlying this kind of mutation.  
  
53 
 
2. MATERIALS AND METHODS 
2.1 Cell culture and manipulation. 
2.1.1 Cell lines generation and growing conditions.  
Mouse Embryonic Fibroblasts (MEFs) are primary cells derived from mice embryos. These 
cells are commonly used as proliferating differentiated cells to study a broad range of 
biological process such as cellular proliferation, cellular senescence, DNA damage response, 
etc. Conditional alleles are commonly used for inducible knock-out, allowing alleles deletion 
after cells derivation from the animal (in this case from the embryos). CRE recombinase is 
the enzyme required to delete the conditional allele, this enzyme could be fused with a 
mutated ligand binding site of the Estrogen Receptor (ER T2), this leads the Cre recombinase 
inactive (because is retained in the cytoplasm) until the ligand (4-hydroxytamoxifen) is 
provided.  
MEFs Ink4a/Arf-/- Ezh2 fl/fl derived from 13.5 dpc embryos from Rosa26 CRE-ERT2, 
Ink4a/Arf knockout mice, used in this work have been described elsewhere [244]. These 
cells were grown in DMEM medium supplemented with 10% fetal calf serum (Euroclone), 
2 mM glutamine (Gibco), 100 U/ml penicillin and 0.1 mg/ml streptomycin (Gibco), 0.1 mM 
non-essential aminoacids (Gibco), 1 mM Na-Pyruvate (Gibco), 50 µM ß-mercaptoethanol-
phosphate-buffered saline (PBS; Gibco) in a CO2 incubator (5% CO2) with reduced oxygen 
tension (3% oxygen). MEFs were passaged every 2 day. The confluent condition consists in 
maintaining MEF in culture for 10 days subjected only to change medium every two days. 
To induce CRE-ERT2 nuclear translocation, cells were treated with 500 nM of 4-
hydroxytamoxifen (4-OHT, Sigma) dissolved in absolute ethanol (Panreac). In starvation 
condition MEFs have been cultured with 1% or 0.1% of fetal calf serum (Euroclone), 2 mM 
glutamine (Gibco), 100 U/ml penicillin and 0.1 mg/ml streptomycin (Gibco), 0.1 mM non-
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essential aminoacids (Gibco), 1 mM Na-Pyruvate (Gibco), 50 µM ß-mercaptoethanol-
phosphate-buffered saline (PBS; Gibco).   
MEF 3T3 fibroblasts expressing a conditional Myc-oestrogen receptor chimaera (3T3MycER) 
immortalized following the 3T3 protocol, were cultured in DMEM medium supplemented 
with 10% fetal calf serum (Euroclone), 2 mM glutamine (Gibco) and 100 U/ml penicillin 
and 0.1 mg/ml streptomycin (Gibco), 0.1 mM non-essential aminoacids (Gibco), 1 mM Na-
Pyruvate (Gibco) and maintained in an incubator at normoxia condition (21% oxygen). 
MEFs were passaged every 2 day. To induce nuclear translocation, cells were treated with 
20nM and 100nM for 24 and 48 hours of 4-hydroxytamoxifen (4-OHT, Sigma) dissolved in 
absolute ethanol (Panreac). These cells were provided by our collaborator in Bruno Amati 
and Stefano Campaner group. 
OKSM MEFs have been described elsewhere [245, 246]. These “reprogrammable MEFs”, 
were derived from mice carrying a double knock in of the four transgenes in the 3’-UTR of 
the Col1a1 locus under the transcriptional control of a doxycycline-responsive promoter. In 
these mice, also, the reverse tetracycline-controlled transactivator (M2-rtTA) is expressed 
from the Rosa26 locus, allowing for induction of expression upon doxycycline 
administration [245, 246]. They were grown in DMEM medium supplemented with 10% 
fetal bovine serum (Euroclone), non-essential amino acids (Gibco), 1% glutamine (Gibco), 
sodium pyruvate (Gibco) and 1% penicillin/streptomycin (Gibco), in a CO2 incubator (5% 
CO2) with reduced oxygen tension (3% oxygen). MEFs were passaged every 2 day. These 
cells were provided by our collaborator in Giuseppe Testa’s group. 
OCI-LY7: B cell lymphoma established from the peripheral blood sample of a 48-year-old 
man with B-cell non-Hodgkin lymphoma (B-NHL, diffuse large B-cell lymphoma, DLBCL) 
carrying the t(8;14) translocation inducing the fusion MYC-IGH and a p53 point mutation. 
These cells were grown in suspension in IMDM medium supplemented with 15% fetal 
bovine serum (Euroclone), non-essential amino acids (Gibco), 1% glutamine (Gibco), 
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sodium pyruvate (Gibco) and 1% penicillin/streptomycin (Gibco), in normoxia incubator 
(21% CO2). 
WSU-DLCL2: B cell lymphoma derived from the pleural effusion of a 41-year-old 
Caucasian man with B-cell non-Hodgkin lymphoma (B-NHL, diffuse large cell lymphoma) 
carrying EZH2 Y641F mutation. These cells were grown in suspension in IMDM medium 
supplemented with 15% fetal bovine serum (Euroclone), non-essential amino acids (Gibco), 
1% glutamine (Gibco), sodium pyruvate (Gibco) and 1% penicillin/streptomycin (Gibco), in 
normoxia incubator (21% CO2). 
SU-DHL-6: B cell lymphoma derived from the peritoneal effusion of a 43-year-old man with 
B-cell non-Hodgkin lymphoma (B-NHL) carrying EZH2 Y641N mutation; assigned to 
GCB-like lymphoma subtype (germinal center B-cell). These cells were grown in suspension 
in IMDM medium supplemented with 15% fetal bovine serum (Euroclone), non-essential 
amino acids (Gibco), 1% glutamine (Gibco), sodium pyruvate (Gibco) and 1% 
penicillin/streptomycin (Gibco), in normoxia incubator (21% CO2). 
All lymphoma cells were provided by Stefano Casola’s group. 
293T cells were grown in DMEM medium supplemented with 10% fetal bovine serum 
(Euroclone), non-essential aminoacids (Gibco), sodium pyruvate (Gibco) and 
penicillin/streptomycin (Gibco), in a CO2 incubator (5% CO2) with standard oxygen tension 
(21% oxygen). These cells have been used for the virus production to infect MEFs. 
 
2.1.2 Transfection  
It is a technique that allows the introduction of DNA into cells. It is performed creating 
Calcium Phosphate-DNA co-precipitates that permeate the cell membrane to permit the 
entry of material. The Calcium Phosphate procedure is based on the combination of HBS 
2X (HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 21 mM, 0,7 mM 
Na2HPO4, 137 mM NaCl, 5 mM KCl, 6 mM Dextrose pH 7,10) with a mix containing 
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calcium chloride (2.5M) and the DNA that has to be delivered. HEPES and calcium chloride 
form a precipitate that binds the DNA.  
Transfection protocol can be exploited to make lentiviral transductions. In this case the 
transfection was performed to obtain medium containing lentiviral particles suitable to 
transduce 293T cell line. 
Transfection was set up using a mix of 8-10 μg of DNA, 6 μg of psPAX2, 3 μg of pMD2.G. 
psPAX2 is a packaging plasmid for the production of viral particles. It has a CAG promoter 
for the expression of Gag, Pol, RRE, REV and TAT. pMD2.G is a VSVG envelope 
expressing plasmid. It has a SV40 promoter.  
The mix of these DNA was combined with 0.125M CaCl2 and free nuclease water to a final 
volume of 500 μl. The mix was then vortexed adding 500 μl of 2X HBS drop-by-drop and 
finally added to cell plates. 
 
2.1.3 Lentiviral infection 
It is a process by which exogenous DNA is transduced into host cells by a virus.  MEFs cells 
were infected using different lentiviral vectors.  
In this process the medium of the transfected cells that contains the virus was harvested and 
centrifuged in order to discard the eventual pellet formed by detached cells and filtrated 
using 0,45 uM filters. The virus-containing medium was then added to the plates where the 
cells that have to be infected were seeded in presence of 5 µg/ml polybrene to increase 
transduction efficiency. A cycle of transduction was repeated after about 24h. To select 
transduced cells puromycin (2ug/mL) was added to cell plates. 
 
2.1.3 Lentiviral vectors 
The used lentiviral vectors are: p-lenti EF1 expressing WT or mutated Y641F or Y641N 
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EZH2, p-lenti pCDH-EF1-MCS-BGH-PGK-GFP-T2A-Puro cDNA Cloning and Expression 
Vector that has been bought from SBI contain a GFP cassette with PGK promoter 
downstream of EF1α strong promoter and a multiple cloning site (MCS) that offer the 
possibility to clone whatever cDNA of interest (indeed I  will use it to clone EZH2 cDNA 
to repeat the reprogramming experiments using the same constructs for every cell lines). 
pEF1-EZH2-ZSgreen has been obtained cloning the EZH2 cDNA devoid of its own ATG 
downstream of EF1α promoter. For the cDNA of WT EZH2 has been used a short isoform 
of the enzyme to count its amino acids. The same cDNA has been modified on the 641 amino 
acids in order to get the point mutation from Tyrosine to Phenylalanine (F) or Asparagine 
(N). The protein is fused with a Zs green cassette and an Internal Ribosome Entry Site (IRES) 
that allows the expression of the Zsgreen. These vectors were provided by our collaborator 
in Stefano Casola’ s group. 
p-lenti for MEF Ink4a/Arf -/- Ezh2 fl/fl has been obtained cloning the EZH2 cDNA devoid 
of its own ATG downstream of EF1α promoter. For the cDNA of WT EZH2 has been used 
a short isoform of the enzyme to count its amino acids. The same cDNA has been modified 
on the 641 amino acids in order to get the point mutation from Tyrosine to phenylalanine 
(F) or Asparagine (N). The protein is fused with a FLAG-tag and an Internal Ribosome Entry 
Site (IRES) that allows the expression of the PuroR gene. These vectors were provided by 
our collaborator in Stefano Casola’ s group. 
 
2.2 Techniques used for protein detection  
2.2.1 Immunoblot analysis 
This method, commonly known as Western blot analysis (WB), allows the detection of 
protein of interest and relative post translational modifications in a protein extract. Protein 
extracts were obtained from cell pellets after lysis with high salt lysis buffer (20mM Tris-
HCl, pH 7.6, 300mM NaCl, 10% glycerol, 0.2% (v/v)) Igepal (Sigma-Aldrich, cat. CA 630), 
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incubating for 30 minutes on ice, sonicated with Bioruptor Diagenode (B435) with 10 cycles 
of pulse 30’’ ON+30” OFF and centrifuging at 10000 x g for 30’ at 4°C, and recovering the 
supernatant. Total extracted proteins were quantified with Bradford assay (Bio- Rad, 
cat.30500-0006). Then Laemmli sample buffer was added and samples boiled 10 minutes at 
95 °C. Usually 30-40 μg of protein extracts were loaded onto each lane of 
acrylamide/bisacrylamide gel, and a sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed. Gel-separated proteins were transferred to a 
Protran Nitrocellulose Membrane (Whatman), one hour and 20 minutes at 4 °C, at 100 Volts. 
Membranes were blocked with a solution of TRIS-buffered saline (TBS: 20mM TRIS/HCl, 
pH 7.4, 137 mM NaCl, 2.7 mM KCl) plus 0.1% Tween (TBS-T) containing 5% non-fat dried 
milk. The same milk/TBS-T solution was prepared to dilute primary antibodies, which were 
incubated for one hour at room temperature or ON at 4 °C. After three washes with TBS-T, 
a secondary HRP (horseradish peroxidase)-conjugated antibody (BioRad) was diluted in the 
same solution and incubated for one hour at room temperature. Following three further 
washes in TBS-T, the bound secondary antibody was revealed by ECL method (enhanced 
chemiluminenscence, Amersham) or ECL-plus (Amersham).  
Detection of histone PTMs were performed with the same method.  
 
2.2.2 Immunofluorescence. 
This is a standard technique that allows to spatially locating in single cells the antigens you 
are interested in (such as proteins or nucleotide analogue in genomic DNA in our case). 
Moreover using the confocal microscope it is possible to test the co-localization of 2 or more 
antigens on the same focal plane with a resolution of 200-400nm. 
Indicated MEFs lines were seeded on 0.1% gelatinized glass coverslips, and nuclei were 
eventually prepared by treatment with cold pre-extraction buffer (10 mM Tris HCl pH 7,6, 
100 mM NaCl, 2 mM MgCl2, 0,3 M sucrose and 0,25% Igepal) for 10 min at 4°C. Whole 
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cells or nuclei were fixed at -20°C with 100% methanol for 10 min. Then, fixed cells were 
incubated with primary antibodies diluted in 0.1% tween-TBS for 1 hour at RT, washed and 
incubated with fluorophore-conjugated secondary antibodies. Nuclei were counterstained 
with DAPI and embedded in anti-fade containing glycerol (DABCO). Images were acquired 
using a Leica SP2 confocal microscope. Mender’s co-localization coefficient was calculated 
on the entire Z-stacks images using the jacop tool of the Image J software. 
 
2.2.3 Mass Spectrometry analysis  
Analysis of proteins isolated from tandem purifications was done by mass spectrometry 
(MS), an analytical technique generating spectra of the masses of the atoms or molecules 
present in a sample of material. The sample is ionized by an ion source, and then ions are 
separated on the basis of their mass/charge ratio, and detected by the detector component 
which converts received ions into spectra of the relative abundance of ions as a function of 
the mass-to-charge ratio. The atoms or molecules can be identified by correlating known 
masses to the identified masses. To have higher resolution, two steps in mass analysis are 
made (tandem mass spectrometry or MS/MS). In our proteomic approach, briefly, proteins 
were separated by gel electrophoresis and enzymatically in gel-digested, producing a 
peptides mixture which is separated by liquid chromatography before its injection into the 
mass spectrometer. Protein digestion produces peptides earning each one a typical spectrum; 
in addition, some peptides are produced uniquely by digestion of specific proteins, therefore 
indicating without any doubt the presence of such proteins in the sample. Combining these 
features with computational tools, we were able to match peptide spectra with the proteins 
to which they belong.  
To achieve this, eluted proteins obtained by tandem purifications were separated by 1D 
SDS–PAGE, using 4–12% NuPAGE Novex Bis–Tris gels (Invitrogen, cat. NP0321BOX) 
and NuPAGE® MES SDS running buffer (Invitrogen, cat. NP0002) according to 
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manufacturer’s instructions; gel was stained with Coomassie Blue using a Colloidal Blue 
Staining Kit (Invitrogen, Cat. LC6025). Samples were digested with trypsin (Promega). The 
gel bands were cut and then washed four times with 50mM ammonium bicarbonate, 50% 
ethanol and incubated with 10mM DTT in 50mM ammonium bicarbonate for 1 h at 56°C 
for protein reduction. Alkylation step was performed incubating the sample with 55mM 
iodoacetamide in 50mM ammonium bicarbonate for 1 h at 25°C in the dark. Gel pieces were 
washed two times with a 50mM ammonium bicarbonate, 50% acetonitrile solution, 
dehydrated with 100% ethanol and dried in a vacuum concentrator. Digestion was performed 
using 12.5 ng/ml trypsin in 50mM ammonium bicarbonate and incubated for 16 h at 37°C 
for protein digestion. Supernatant was transferred to fresh tube, and the remaining peptides 
were extracted by incubating gel pieces two times with 30% acetonitrile (MeCN) in 3% 
trifluoroacetic acid (TFA), followed by dehydration with 100% acetonitrile. The extracts 
were combined, reduced in volume in a vacuum concentrator, desalted and concentrated 
using RP-C18 StageTip columns and the eluted peptides used for mass spectrometric 
analysis.  
Peptide mixtures were separated by nano-LC/MSMS using an Agilent 1100 Series nanoflow 
LC system (Agilent Technologies), interfaced to a 7-Tesla LTQ-FT-Ultra mass spectrometer 
(ThermoFisher Scientific, Bremen, Germany). The nanoliter flow LC was operated in one 
column set-up with a 15-cm analytical column (75 µm inner diameter, 350 mm outer 
diameter) packed with C18 resin (ReproSil, Pur C18AQ 3 mm, Dr Maisch, Germany). 
Solvent A was 0.1% FA and 5% ACN in ddH2 O and Solvent B was 95% CAN with 0.1% 
FA. Samples were injected in an aqueous 0.1% TFA solution at a flow rate of 500 nl/min. 
Peptides were separated over a gradient of 0–40% Solvent B over 90 min followed by a 
gradient of 40–60% for 10 min and 60–80% over 5 min at a flow rate of 250 nl/min. The 
mass spectrometer was operated in a data-dependent mode to automatically switch between 
MS and MS/MS acquisition. In the LTQ-FT full scan MS spectra were acquired in a range 
of m/z 300–1700 by FTICR with resolution r =100 000 at m/z 400 with a target value of 1 
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000 000. The five most intense ions were isolated for fragmentation in the linear ion trap at 
a target value of 5000. The nanoelectrospray ion source (Proxeon, Odense, Denmark) was 
used with a spray voltage of 2.4 kV. Sing wide band activation mode was 35%. Normalized 
collision energy was set to 35%, and activation time to 10 ms; spray voltage, 2.2 kV; no 
sheath and auxiliary gas flow; heated capillary temperature, 275ºC; predictive automatic 
gain control (pAGC) enabled, and an S-lens RF level of 65%. For all full-scan measurements 
with the Orbitrap detector, a lock mass ion from ambient air (m/z 445.120024) was used as 
an internal calibrant as described previously [247]. 
 
2.2.4 Acidic extraction of histones and Immunopurification 
Ink4a/Arf -/- Ezh2 fl/fl MEFs were harvested, resuspended in N-Buffer (15 mM HEPES, pH 
7.5, 10% sucrose, 0.5% Triton X-100, 0.5 mM EGTA, 60 mM KCl, 15 mM NaCl, 30 ug/ml 
Spermine, 30 ug/ml Spermidine, 1 mM DTT, 3 mM NaButyrate, 5 mM NaF, 5 mM Na-
Pyrophosphate, 5 mM ß-glycerophosphate) with fresh addition of a protease inhibitor 
cocktail (Calbiochem) at a cell density of 125x106 cells/ml and lysed 10 min at 4ºC with 
gentle stirring. Lysate was centrifuged onto a 10% sucrose cushion (107 cells/cushion) at 
4000 rpm for 30 min and washed twice in ice cold 1x PBS. Histones were extracted in 0.4 
N HCl overnight at 4ºC with gentle stirring, extensively dialyzed in 0.1 M acetic acid and 
dried out. Histone pellets were re-suspended in water and quantified with Bradford assay 
and denature in Laemmli sample buffer (Invitrogen).  
 
2.2.5 In-gel digestion of histones for MS analysis 
Histones were separated on 1D SDS-PAGE, using 4–12% NuPAGE® Novex Bis–Tris gels 
(Invitrogen) and NuPAGE® MES SDS running buffer (Invitrogen) according to 
manufacturer's instructions. The gel was stained with Coomassie Blue using Colloidal Blue 
Staining Kit (Invitrogen). Protein band corresponding to histone H3 was excised from the 
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gel, de-stained with 50% acetonitrile (MeCN) diluted in H2O to be then chemically alkylated 
by incubation with acetic anhydride-D6 (Sigma 175641) 1:9 ratio in 1M NH4HCO3 as 
previously described [248]. After 3h at 37 °C with strong shaking (1400 rpm), gel pieces 
were washed by increasing concentration of MeCN. In-gel digestion was performed with 7.5 
ng/µl trypsin (Promega V5113) in 50 mM NH4HCO3 at 37 °C overnight. Supernatant was 
transferred to fresh tube, and the remaining peptides were extracted by incubating gel pieces 
two times with 30% MeCN in 3% trifluoroacetic acid (TFA), followed by dehydration with 
100% MeCN. The extracts were pooled, reduced in volume in a vacuum concentrator, 
desalted and concentrated using a combination of in house-made RP-C18/Carbon and a 
strong cation exchange (SCX) solid phase extraction (SPE) StageTip [249]. Briefly, digested 
peptides loaded on combined RP-C18/Carbon and SCX StageTip were eluted with high 
organic solvent (80% MeCN) and NH4OH, respectively. Eluted peptides were lyophilized, 
re-suspended in 0.1% TFA and 0.5% acetic acid in ddH2O, pooled and subjected to liquid 
chromatography and tandem mass spectrometry (LC-MS/MS).  
 
2.2.6 Data analysis for histone PTMs MS/MS 
The mass spectrometric raw data were analyzed with the MaxQuant software (version 
1.1.1.25) [250, 251]. A false discovery rate (FDR) of 0.01 for proteins and peptides and a 
minimum peptide length of 6 amino acids were required. In order to improve mass accuracy 
of the precursor ions, the time-dependent recalibration algorithm of MaxQuant was used. 
The MS/MS spectra were searched by Andromeda engine against the IPI human database 
(containing 87,061 entries) combined with 262 common contaminants and concatenated 
with the reversed versions of all sequences [252]. Enzyme specificity was set to Arg-C and 
maximum of three missed cleavages were allowed. Peptide identification was based on a 
search with an initial mass deviation of the precursor ion of up to 7 ppm. The fragment mass 
tolerance was set to 20 ppm on the m/z scale. Variable modifications included: deuterate 
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acetylation (D3-acetylation) (+45.0294 Da) on Lysine, Lysine mono-methylation 
(calculated as the sum of the masses of D3-acetylation (+45.0294) and mono-methylation 
(+14.016 Da)), dimethylation (+ 28.031 Da) and tri-methylation (42.046 Da), Lysine 
acetylation (+ 42.010 Da), Methionine oxidation (+ 15.995 Da) and N-terminal protein 
acetylation. D3-acetyl chemical alkylation results in a delta mass of 45.0294 Da for each 
group added either to the unmodified or mono-methylated Lysine, allowing the 
discrimination of isobaric modified peptides. Output table from MaxQuant were filtered with 
the following criteria: peptides with a low score (cut-off score value, 60) [253] and with 
more than 5 putative PTMs per peptide were removed. Redundant peptides were filtered so 
that only the peptide with the highest Andromeda score among peptides with the same 
identification was included. The filtered data were then subjected to manual validation using 
Qual Browser version 2.2 (ThermoFisher Scientific). Estimation of relative species 
percentage (RS%) calculated Extracted ion chromatograms (XIC) were constructed for 
precursor ions with mass tolerance of 10 ppm and mass precision up to 4 decimal places 
using Qual Browser version 2.2. Peak areas for both unmodified and modified peptide 
species were measured within the same retention time interval. 
Relative species percentage (RS%) for (27-40) peptide derived from MEF Ink4a/rf, Ezh2 
fl/fl transduced with empty vector  or overexpressing EZH2 WT or EZH2 Y641N were 
calculated dividing the peak area relative to each peptide species divided by the sum of peak 
areas for all peptide species sharing the same amino acid sequence. Specific delta masses 
relative to modified sequence of (27-40) peptide from H3 was further included in 
Andromeda configuration module (AndromedaConfig.exe). 
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2.2.7 Cell cycle analysis with FACS 
Indicated MEFs lines were subjected to cell cycle analysis by means of Fluorescence 
Activated Cell Sorting (FACS) taking advantage of specific dye intercalating the DNA 
(Propidium Iodide) and nucleotide analogue (BrdU) previously pulsed into cells.  
Cell events were acquired at FACSCalibur flow cytometer (BD Biosciences) and analyzed 
with FlowJo 8.5.3 software (Tree Star). For cell cycle analysis, MEF Ink4a/rf, Ezh2 fl/fl 
were cultured as previously described and pulsed with 33 µM 5-bromo-2-deoxyuridine 
(BrdU) for 45 min. Cells were washed with PBS, fixed with 75% ethanol, denatured with 
2N HCl and neutralized by 0.1 M Borax. Cell staining was performed in blocking buffer 
solution using mouse anti-BrdU as primary antibodies; anti-mouse IgG-FITC conjugate was 
used as secondary antibodies. Cells were finally re-suspended in PBS containing 2.5 ug/mL 
Propidium Iodide in presence of RNase A and analyzed with FACSCalibur flow cytometer. 
Collected data were analyzed with Cell Quest Pro (BD Biosciences) and the single cell 
fluorescence intensity values of the gated populations were retrieved using FCS Assistant 
software. 
 
2.3 Assays for detection of DNA modifications and 
protein binding to DNA. 
2.3.1 Chromatin Immunoprecipitation (ChIP) 
ChIP (chromatin immunoprecipitation) technique is used to investigate protein-DNA 
interaction studies. The fundamental principle is the cross-linking between DNA and DNA-
associated proteins that can be achieved by treating (“fixing”) cells with formaldehyde or 
UV rays. Cross-linked chromatin is sheared by sonication to generate fragments of 300 - 
1000 base pairs (bp) in length. Through immunoprecipitation, proteins of interest coupled to 
DNA are isolated by means of antibodies. Chemical cross-linking is reversible, thus DNA 
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can be separated from associated proteins and analyzed, both by high throughput sequencing 
and Real Time quantitative PCR. Briefly, 1% formaldehyde cross-linked chromatin was 
resuspended in IP buffer (70 mM TRIS/HCl pH=8.0, 5 mM EDTA, 100 mM NaCl, 0.3 % 
sodium dodecyl sulfate or SDS, 1.7% TRITON X-100), fragmented by sonication using a 
Digital sonifier 450 (Branson) to an average size of 200–500 bp to perform ChIP on 
H3K27me2 and H3K27me3 modifications and of 500-1000 bp to make proteins ChIP and 
immunoprecipitated ON with 5 μg of indicated antibodies per milligram of sonicated 
chromatin. Then protein A sepharose beads (GE Healthcare, cat. 170780-01; 30 μl slurry per 
milligram of sonicated chromatin; 1 mg of chromatin was used for each protein precipitation; 
500 ug were used for histone PTMs) were added and incubated 2 h at 4°C, followed by three 
washes with “low salt” wash buffer (20 mM TRIS/HCl pH8.0, 2 mM EDTA, 150 mM NaCl, 
0.1% SDS, 1% TRITON X-100), and one in “high salt” wash buffer (20 mM TRIS/HCl 
pH8.0, 2 mM EDTA, 500 mM NaCl, 0.1% SDS, 1% TRITON X-100) were performed. De-
crosslinking was made at 65°C ON. Eluted DNA was purified using QIAquick PCR 
purification kit (Qiagen). 
 
2.3.2 ChIP Rx: Reference exogenous genome ChIP  
Briefly, 1% formaldehyde cross-linked chromatin was resuspended in IP buffer (70 mM 
TRIS/HCl pH=8.0, 5 mM EDTA, 100 mM NaCl, 0.3 % sodium dodecyl sulfate or SDS, 
1.7% TRITON X-100), fragmented by sonication using a Digital sonifier 450 (Branson) to 
an average size of 200–500 bp to perform ChIP on H3K27me2 and H3K27me3 
modifications. Then after to have added 5% of drosophila S2 cells chromatin to the samples 
subjected to immunoprecipitation, the 1% input is taken. Subsequently ChIP is performed 
overnight with 5 μg of indicated antibodies per milligram of sonicated chromatin. The 
following day protein A sepharose beads (GE Healthcare, cat. 170780-01; 30 μl slurry per 
500 ug chromatin were used for histone PTMs) were added and incubated 2 h at 4°C, 
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followed by three washes with “low salt” wash buffer (20 mM TRIS/HCl pH8.0, 2 mM 
EDTA, 150 mM NaCl, 0.1% SDS, 1% TRITON X-100), and one in “high salt” wash buffer 
(20 mM TRIS/HCl pH8.0, 2 mM EDTA, 500 mM NaCl, 0.1% SDS, 1% TRITON X-100) 
were performed. De-crosslinking was made at 65°C overnight. Eluted DNA was purified 
using QIAquick PCR purification kit (Qiagen). 
 
2.3.3 High throughput ChIP sequencing (ChIPseq) 
The DNA retrieved from ChIP experiments were used for ChIPseq libraries preparation with 
the Illumina ChIPSeq Sample Prep kit (IP-102-1001) and multiplexing oligonucleotide kit 
(PE-400-1001) by our internal genomic facility. DNA libraries were quantified using a high 
sensitivity DNA Chip on Bioanalyzer instrument (Agilent) and used for cluster generation 
and sequencing using the HiSeq 2000 platform (Illumina) following the protocol of the 
manufacturer. 
 
2.3.4 ChIP-Quantitative Real Time PCR (RT-qPCR) 
The real-time quantitative polymerase chain reaction (qPCR), allows the detection and 
relative quantification of a specific DNA sequence in a sample. Unspecific fluorescent dye 
(SYBR green) intercalates with double-strand DNA, specifically amplified through PCR 
made with specific oligonucleotide probes (primers). For a short period of the reaction, DNA 
amplification is exponential, therefore it can be described by a mathematical function, 
allowing DNA quantification. This technique can be used both to detect the amount of a 
DNA sequence (such as target genes in a ChIP experiment), or the abundance of a cDNA 
derived from an RNA sample. All the qPCRs were carried out using Fast SYBR Green 
(Applied Biosystem) as dye. Lists of primers used are available in Table 4.  
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2.3.5 ChIP sequencing data analysis.  
Each ChIP-seq data with spike-in was aligned to mouse (mm9) and drosophila (dm6) 
reference genome using Bowtie (PMID 19261174) separately. Alignment was executed 
favouring only unique alignments, and duplicates were removed for downstream analysis. 
Peak calling was for all samples was performed with macs2 (PMID 18798982). Broader 
peaks were generated by enabling the --broad option.  
We derived a normalization factor for individual dataset as described in publication (PMID 
25437568), where α, for each sample, is such that the resulting drosophila signal was 
equilibrated across all samples. The mathematical derivation of the normalization factor α is 
as follows: 
Let: 
• α = normalization factor 
• β = reference signal from the reference sample (drosophila) 
• Nd = total number of reads from a sample aligning to the reference genome 
• r = percentage of the sample comprised of reference sample 
as the reference signal should always be the same, it can be written as 
ߚ = ߙ
ܰ݀
ݎ
 
And, since β is always the same, it can be arbitrarily set it to any value, and for convenience 
it was set to 1. 
1 = ߙ
ܰ݀
ݎ
 
Then above equation can be reformed as 
ߙ =
ݎ
ܰ݀
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Since r is the same for all experiments in this work, it can be further simplified to 
ߙ =
1
ܰ݀
 
Therefore the normalization constant used is 1 over the number of reads mapping to 
drosophila per million. This is applied to all samples. 
For profiling, we considered center of target region and extended to defined length both up 
and downstream. Extended region was further broken down into smaller bins of 50 bp in 
size. Irrespective of modification, normalized reads with or without normalization factor for 
their respective sample within each bin were computed and represented as heatmap.   
 
2.4 Methods for RNA analysis 
2.4.1 RNA sequencing (RNA-seq) 
High throughput RNA sequencing is a technique allowing the whole transcriptome profiling 
of a cell population. In our cases, a selection for poly adenilated mRNA was performed.  
Total RNAs from indicated MEFs lines were extracted using the Qiagen RNeasy Plus RNA 
extraction kit. Retrieved RNA was checked for integrity on a Bioanalyzer instrument by 
picoRNA Chip (Agilent) and then converted into libraries of double stranded cDNA suitable 
for next generation sequencing on the Illumina platform. At this purpose, the Illumina 
TruSeq v.2 RNA Sample Preparation Kit was used following manufacturer’s 
recommendations. Briefly, 5 μg of total RNA were subjected to mRNA purification by 
means of poly-T oligo-attached magnetic beads, then fragmentation was performed 
exploiting divalent cations contained in the Illumina fragmentation buffer and high 
temperature. First, cDNA strand was synthesized with random oligos by Reverse 
Transcriptase SuperScript III (Invitrogen). Second, cDNA strand synthesis was performed 
by DNA polymerase I and Rnase H. Then, DNA fragments were blunt ended and adenylated 
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at 3’ extremities before ligating specific Illumina oligonucleotides adapters. Resulting 
fragments were enriched performing 15 cycles of PCR reaction using proprietary Illumina 
primers mix. Prepared libraries were quality checked and quantified using Agilent high 
sensitivity DNA assay on a Bioanalizer 2100 instrument (Agilent Technologies). 
 
2.4.2 RNA sequencing data analysis. 
Sequencing data was aligned to mouse reference genome (mm9) using Tophat (PMID 
23618408). Differentially expressed genes (DEGs) were identified using DESeq (PMID 
20979621). We regarded genes as differentially expressed with fold change greater than or 
equal to 3 and with adjusted p-value less than 0.05. 
 
2.4.3 Real Time quantitative PCR 
Total RNA was extracted with the Qiagen RNeasy Plus RNA extraction kit. The RNA is 
subsequently retro-transcribed usingThe ImProm-II™ Reverse Transcription System that is 
a kit that allows obtaining first-strand cDNA in preparation for PCR amplification according 
to the manufacturer’s instructions. Reverse-transcrption real-time quantitative PCR (RT-
qPCR) was carried out using Fast Sybergreen as previously described. Primers are listed in 
Table 5. 
 
2.5 Reprogramming 
2.5.1 Infection and selection of OKSM MEFs  
OKSM MEFs were infected as in 3.1.3 with either the Empty vector (expressing also the 
GFP) or vectors expressing WT or mutant EZH2 (expressing also the ZsGreen protein), with 
two independent vector productions for each EZH2 condition. After 5 days cells were sorted 
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on a BD influx (BD) on the basis of GFP or ZsGreen expression, selecting cells that 
fluoresced at least 1 log over the background (uninfected MEFs were used as negative 
control). 
 
2.5.2 Reprogramming experiment 
Plates were incubated with gelatin 0.1% for 30’ at 37°C before mytomycin-C inactivated 
MEFs were plated (333.000 cells/well of a six-well plate) in MEF medium. The day after 
OKSM MEFs were plated on top of this feeder-layer (5000 cells/well of a six well plate) in 
MEF medium. In an additional well we plated the same amount of cells without feeder-layer 
was used, in order to perform count at the day of induction. The day after, after counting 
cells with a burker chamber, we induced reprogramming by incubating cells with iPSC 
medium. Doxycicline (2 µg/mL) was added in all conditions except for the UT control 
(untreated), and medium was changed every day until day 14. 
miPSC medium 
Product Cat. Nr. Producer Final mix (600 ml) 
Advanced D-MEM/F-12 (1X) 
liquid  12634010 
Thermo 
Fisher 500 mL 
Knockout™ Serum Replacement 10828028 Thermo Fisher 100 mL 
Sodium Pyruvate MEM 100 mM, 
liquid 11360039 
Thermo 
Fisher 5 mL 
MEM Non Essential Amino Acids 
(100X), liquid 
without L-Glutamine. 
11140035 Thermo Fisher 5 mL 
Penicillin-Streptomycin, liquid 15140122 Thermo Fisher 5 mL 
L-Glutamine 200 mM (100X), 
liquid 25030-024 Thermo Fisher 5 mL 
2-Mercaptoethanol, 50 mM 
(1000X) 31350-010 Thermo Fisher 0.5 mL 
mLIF n.a. Transgenic Facility 1.2 mL 
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2.5.3 Assessment of GFP+ colonies 
One well from each condition was analyzed under a fluorescence microscope (EVOS, 
Thermo Fisher Scientific) to assess the fraction of GFP+ colonies. Colonies were manually 
counted and the fraction was assessed as the number of GFP+ colonies on the total of 
colonies in the well. 
2.5.4 Alkaline phosphatase staining 
A solution made of Citrate, Acetone and Formaldehyde was used to fix cells for 45 seconds 
after a wash in DPBS. Cells were rinsed in ddH2O for 30 seconds and the staining solution 
(Vector RED Alkaline phosphatase substrate kit, Vector Labs) was added to cells for 30 
minutes. Cells were rinsed in ddH2O and imaged for the presence of a red precipitate. 
Colonies were counted manually and the efficiency of reprogramming was computed by 
dividing the number of alkaline phosphatase positive colonies by the number of counted 
cells the day of induction. 
 
2.6 Antibodies 
2.6.1 Antibodies used for Immunoblot and immunoprecipitation 
analyses 
For Western blots the following antibodies were used: mouse anti-Vinculin (Sigma-Aldrich, 
Cat. V9131), mouse anti-Eed [254], goat anti-Suz12 (Santa Cruz, Cat. sc-46264), rabbit anti-
FLAG (Sigma, Cat. F7425), goat anti-Lamin B (Santa Cruz, Cat. sc6216), mouse anti-Ezh2 
[254].For histone PTMs detection of the following  antibodies were used: rabbit anti-H3 
(Abcam, Cat. 1791), mouse anti-H3K27me1 (Active Motif, Cat. 61015), rabbit anti-
H3K27me2 (Cell Signaling, Cat. 9728), rabbit anti-H3K27me3 (Cell signaling, Cat. 9733). 
 
72 
 
2.6.2 Antibodies used for ChIP analyses 
In ChIP experiments, the following antibodies were used: rabbit anti-Suz12 (Cell signaling, 
Cat. 3737), rabbit anti-H3K27me2 (Cell Signaling, Cat. 9728), rabbit anti-H3K27me3 (Cell 
signaling, Cat. 9733).  
2.6.3 Antibodies used for immunofluorescence staining and 
FACS 
For immunofluorescence and FACS analysis, the following antibodies were used: rabbit 
anti-Suz12 (Cell Signaling, Cat. 3737), rabbit anti-H3K27me3 (Cell Signaling, Cat. 9733), 
mouse anti-BrdU (BD Biosciences, Cat. 347580), Alexa fluor 488 conjugated donkey anti-
rabbit (Invitrogen, Cat. A21206), FITC conjugated donkey anti-mouse (Jackson 
Immunoresearch, Cat. 715095150). 
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2.7 Primers 
ChIP qPCR primers 
oligo name  sequence (5'-3') 
WT1 forward  GTCGGAGCCCATTTGCTG 
WT1 reverse CAGTGAGACGAGGCTCCCAC 
Hoxd9 forward GGATAATCGCCTAGGTGTGACTTAG 
Hoxd9 reverse CATCTCTTCTTGCCTCTCTGGG 
Utp6 forward AGCTAGGCAGCAGTCACCAT 
Utp6 reverse CAGTTGCGCAATAGTGTCGT 
c-Myc forward GGAGTGGTTCAGGATTGGGG 
c-Myc reverse AAGTTCACGTTGAGGGGCAT 
Reg1 forward GACCATGTCCAGAAGACAGAAG 
Reg1 reverse CTAAGGCTCAGGAAACAGTGTAG 
Reg2 forward GGCCTGCTGGGTTTAGATAAT 
Reg2 reverse TCTGAGCTGAAAGCACATCC 
Reg3 forward AGGAATGGCTATGTGGTTAAGG 
Reg3 reverse TGCCCTGGAAATGGAGTTATG 
Reg4 forward GCCCAAGGTACATGTTTGTATTG 
Reg4 reverse TATCTCTGTCGAGCCCTGTAA 
Reg5 forward CCCGTGCTCTTACACATTCT 
Reg5 reverse CCTGACCTCTTCTGCTTTAGTT 
Reg6 forward GAGCCTGCACAACTCTTCTAT 
Reg6 reverse AGAATTTCCCACCACTCCTTAC 
chr5 forward TGTCTGTTTCCTGCCGGTTA 
chr5 reverse AGCCAAGCCATAAAAATTCGCA 
Chr13#1 forward CGGAAACTTTTCCAGTGGCG 
Chr13#1 reverse CAGTCCAGAGACCCCCTCAT 
Chr13#2 forward CGTTTCCACCGCACCAATTT 
Chr13#2 reverse TGCGTTTGACAGCTATGACCT 
Chr11 forward CCAGCACACACAGCAATCAG 
Chr11 reverse AAGCTGGGAGAAAAGCAGGC 
Chr7 forward CCCCTTCCCATTGCATGGAT 
Chr7 reverse CTTTTCACAGCGACTGGCAC 
 
Table 4: Primers used in ChIP qPCR. 
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Reverse transcription qPCR primers 
oligo name  sequence (5'-3') 
Gata6 forward TGGAAGACACCCCAATCTCG  
Gata6 reverse ACATGGCCCCACAATTGACA 
FoxA2 forward GCGGCCAGCGAGTTAAAGTAT 
FoxA2 reverse GTTGCTCACGGAAGAGTAGC 
Tgm2 forward TAAGAGTGTGGGCCGTGATG 
Tgm2 reverse TTTGTTCAGGTGGTTGGCCT 
Asb4 forward GGAGACGAGCCATTCCTGAT 
Asb4 reverse GACAGGTGCATGAGGGTTCT 
Gnao1 forward AAGTCCCCACTCACCATCTGC 
Gnao1 reverse TACTGCCCTTGGATGTGAGCC 
Gsn forward CCAAAGTCGGGTGTCTGAGG 
Gsn reverse CAAACTTCTCCACACGCCAG 
 
Table 5: Primers used in RT-qPCR. 
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3. RESULTS 
3.1 MEF model system 
In order to characterize and dissect the molecular mechanisms underlying the described gain 
of function mutations occurring on the Polycomb subunit EZH2 (EZH2-Y641N/F) we 
decided to use mouse embryonic fibroblasts (MEFs) as model system. MEF are indeed easy 
to manage for experimental purpose. I used MEFs, derived from E13.5 conditional Rosa26 
CRE-ERT2, Ezh2 fl/fl, Ink4a/Arf knockout embryos, that can be maintained in culture for 
long period when cultivated at 3% of oxygen. The other reason was to characterize EZH2 
putative oncogenic potential independently of the B-cell context in a tumor-prone 
background, since the Ink4a/Arf locus and its downstream targets pRB and p53, are 
frequently lost in tumors by genetic mutations or loss of heterozygosity (LOH). To evaluate 
the role of EZH2 gain of function mutations, I infected MEFs with lentiviral vectors, 
expressing either the human wild type form of EZH2 (EZH2 WT) or EZH2 carrying a 
mutation within the SET domain where tyrosine 641 is converted into either a phenylalanine 
or an asparagine (Y641F and Y641N mutants, respectively). As transduction control, I used 
an empty vector. All constructs express also Puromycin resistance gene, by means of an 
Internal Ribosome Entry Site (IRES), to allow selection of stably infected cells (Fig. 6).  
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Figure 6: Schematic representation of the employed lentiviral vectors and experimental approach. 
Top panel: Schematic representation of lentiviral vectors harboring either the human form of EZH2 WT or 
the mutated form of EZH2 on Y641 from tyrosine to asparagine (Y641N) or from tyrosine to phenylalanine 
(Y641F) or no transgene (Empty vector) (purple box), under the control of the EF1α promoter. The protein is 
fused with a FLAG-tag and an Internal Ribosome Entry Site (IRES) allows the expression of the PuroR gene. 
Bottom panel: scheme of the viral transduction protocol in MEFs and selection in puromycin.  
 
3.2 MEF harboring Y641N/F EZH2 show imbalance in 
H3K27 methylation status as in lymphoma cells 
To assess the impact of EZH2 GOF mutants on global levels of H3K27 modifications, I 
performed western blot analyses for the three H3K27 methylation states on total protein 
extracts obtained from these cells lines. I showed that only cells expressing EZH2 GOF 
mutants (EZH2 Y641F/N), but neither EZH2 WT, nor MEFs harboring the empty vector, 
had increased H3K27me3 levels with concomitant decrease in H3K27me2 and H3K27me1 
levels (Fig. 7). Importantly, this pattern of histone modifications caused by the ectopic 
expression of EZH2 GOF mutants mirrors the one observed in the WSU-DLCL2 lymphoma 
cell line, naturally carrying the Y641F mutation reported in Sneeringer paper [229]. 
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Figure 7: MEFs overexpressing mutant EZH2 rearrange H3K27 methylation balance. 
Immunoblot using the indicated antibodies on total protein extracts obtained from MEFs expressing the empty 
vector (first lane), EZH2 WT or the mutants EZH2 Y641F and EZH2 Y641N. H3 served as loading control. 
The asterisk indicates an aspecific band while the arrow corresponds to EZH2 band. 
 
To check whether this effect was due to the co-presence of both the WT and the mutated 
form of EZH2, I depleted the endogenous Ezh2 allele by CRE-ERT2 treating cells with 500 
nM of 4-hydroxytamoxifen (4-OHT). Upon deletion, I could show that, only in the presence 
of a WT Ezh2 allele, the EZH2 Y641N can lead to the accumulation of H3K27me3 (Fig. 8).  
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Figure 8: EZH2 Y641N mutant needs its WT counterpart to alter the methylation status of H3K27. 
Immunoblots using the indicated antibodies with protein extracts obtained from MEFs expressing EZH2 WT 
or the mutant Y641N in the presence of the endogenous WT copy of Ezh2 (EtOH-treated, Ezh2fl/fl), or in the 
absence of it (OHT-treated, Ezh2 -/-). H3 and Vinculin served as loading controls.  
 
In order to obtain a more quantitative evaluation of H3K27 modifications, meaning their 
relative abundance, in collaboration with Tiziana Bonaldi’s group I performed on two 
biological replicates, in which I firstly assessed the amount of H3K27me2 and H3K27me3 
(Fig. 9A), a quantitative mass spectrometry analysis on the histone H3 bulk in cells 
expressing different EZH2 mutations. Indeed I could score a reduction in H3K27me2 and a 
concomitant increase in H3K27me3 levels in cells expressing the mutant form of EZH2 (Fig. 
9B and 9C).  
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Figure 9: Quantification by mass spectrometry of H3K27 methylation status. 
A: Immunoblots using the indicated antibodies with total protein extracts obtained from two biological 
replicates of MEFs expressing the empty vector or either EZH2 WT or the indicated mutant EZH2 Y641N 
subjected to MS. H3 served as loading control. B: Barplot showing the quantification of the relative abundance 
of the modifications by mass spectrometry (MS/MS). C: Magnification of H3K27me3 barplot as in B. 
 
3.3 Distribution of H3K27 modifications and PRC2 
localization  
In order to characterize the distribution of the increased levels of H3K27me3, I performed 
ChIP analyses in MEFs expressing the WT and the mutated forms of EZH2 (Y641N) using 
H3K27me3 and Suz12 specific antibodies. First of all, I looked at known PcGs target genes 
by real-time quantitative PCR (ChIP-qPCR). Even if these cell lines present a clear global 
specific increase of H3K27me3 and decrease in H3K27me2, as assessed by Western blot 
analyses (Fig. 7), surprisingly by ChIP-qPCR I found that H3K27me3 and Suz12 levels were 
reduced at the HoxD9 and WT1 promoters (Fig. 10A) that are typical Polycomb targets. I 
then coupled ChIP to high-throughput DNA sequencing (ChIP-seq) to assess genome-wide 
the distribution of H3K27me3 mark and Suz12. ChIP-seq analysis showed indeed a loss in 
H3K27me3 in TSS enriched in H3K27me3 both for the modification and for PRC2 
occupancy (Fig. 10B). To validate the results of the sequencing, I analyzed by ChIP-qPCR 
regions shown to be enriched for H3K27me3 mark in our ChIP-seq analysis and indeed I 
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could confirm regions characterized by an increase in H3K27me3 compared to WT-EZH2 
expressing MEFs (Fig. 10C). Coherently, also Suz12, a core member of the PRC2 complex, 
is overall displaced from transcription start sites (Fig. 10A and 10B). 
 
 
Figure 10: Traditional ChIP-seq analysis is not able to reveal an increase in H3K27me3 upon expression 
of the Y641N mutant. 
A: ChIP-qPCR analyses in MEFs expressing the empty vector or EZH2 WT or mutated EZH2 Y641N 
performed for the indicated marks on Hoxd9 and Wt1 (as typical Polycomb targets), Utp6 (known to be 
enriched in H3K27me2) and Myc (negative region) loci. ChIP enrichments are normalized to input. B: Heat 
map of the normalized H3K27me3 and Suz12 ChIP-seq signals in MEFs harboring EZH2 WT or EZH2 Y641N 
mutation for H3K27me3-enriched promoters +/- 5kb from TSS. C: Validation of ChIP-seq by ChIP-qPCR 
analyses in regions enriched in H3K27me3. ChIP enrichments are normalized to input. 
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I hypothesized that this controversial result could imply a saturation problem in ChIP 
analyses because the same amount of antibody is applied in the two conditions. Indeed WT 
MEFs have a defined number of H3K27me3 enriched regions, while, according to the 
previous results, a higher number of (or more enriched) targets should be present upon 
expression of EZH2 mutations. In those circumstances, the antibody binds a larger amount 
of targets, with a reduction in the local number of ChIP-seq aligned reads with respect to the 
WT EZH2. 
To solve these problems, I decided to investigate the genome-wide distribution of 
H3K27me3 using a quantitative ChIP with reference exogenous genome using specific 
antibodies against H3K27me3 (ChIP-Rx). 
ChIP-Rx [255] is an innovative method that allows performing genome-wide quantitative 
comparisons of histone modification status across cell populations using a constant quantity 
of a reference epigenome or “spike-in”.  In our case I mixed the chromatin of MEFs 
expressing the WT or mutated Y641N form of EZH2 cell lines with an amount of Drosophila 
S2 cell chromatin corresponding to the 5% of the total amount of chromatin obtained from 
MEFs in order to enable correction of ChIP efficiency. After sequencing and mapping, 
ChIPseq reads are normalized to the percentage of reference genome reads in the sample. 
ChIP-Rx indeed enables the discovery and quantification of dynamic epigenomic profiles 
across mammalian cells that would otherwise remain hidden using traditional normalization 
methods. Indeed by this approach, we computed the cumulative H3K27me3 signal and could 
show that H3K27me3 levels were increased upon proper normalization, in agreement with 
the Western blot results. Overall this analysis clearly highlights, with all its potential 
limitations, the fundamental role of the “spike-in” normalization to allow a more accurate 
quantification of ChIP-seq results. Moreover, we could observe a general increase of 
deposition of this modification not only at promoters (Fig. 11A) but also at genome-wide 
level as demonstrated by the analysis along the entire lengths of chromosomes (Fig. 11B), 
highlighting the role of mutant EZH2 Y641N in increasing the global amount of the 
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H3K27me3 mark. 
 
 
Figure 11: ChIP-Rx shows gain of H3K27me3 in MEFs overexpressing mutant EZH2. 
A: Heat map of the normalized H3K27me3 ChIP-seq signal in MEFs harboring EZH2 WT or EZH2 Y641N 
mutation for H3K27me3-enriched promoters +/- 5kb from TSS. Drosophila S2 spike-in normalization has been 
applied. B: Genome-wide deposition of the H3K27me3 modification along chromosomes lengths in MEFs 
expressing the empty vector (in blue) or EZH2 WT (in black) or EZH2 Y641N mutation (in red).  
 
3.4. Relocalization  
In order to see whether genome wide deposition of the H3K27me3 mark could results in 
altered nuclear localization of target genes, I performed immunofluorescence analysis of the 
H3K27me3 modification in the MEFs expressing the WT or the mutant form of EZH2. By 
confocal microscopy, I observed a strong accumulation of H3K27me3 at the nuclear 
periphery in cells ectopically expressing the Y641N mutated form of the enzyme compared 
to the normal dispersed localization pattern observed in cells expressing the WT form (Fig. 
12, top panel). Indeed in MEF expressing the mutant form of the enzyme the modification 
colocalizes with the nuclear lamina (as assessed by Lamin B staining) that typically occupies 
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the periphery of the nucleus and is preferentially associated with gene-poor regions of 
chromosomes. This phenomenon occurred despite the usual distribution/localization of the 
subunit Suz12 (Fig. 12, bottom panel), thus also of the PRC2 complex, both in cells 
ectopically expressing the WT or the mutated form of the enzyme (Fig. 12).  
 
 
Figure 12: H3K27me3 mark is relocalized to nuclear periphery upon overexpression of mutant EZH2. 
Top panel: Confocal analysis of immunofluorescence staining with H3K27me3 (green) and Lamin B (red) 
specific antibodies in MEFs expressing EZH2 WT or EZH2 Y641N. Cell nuclei were stained with DAPI 
(blue). Bottom panel: Confocal analysis of immunofluorescence staining with Suz12 (green) and Lamin B 
(red) specific antibodies in MEFs expressing EZH2 WT or EZH2 Y641N. Cell nuclei were stained with 
DAPI (blue). 
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3.5. Transcriptional analyses  
Since PRC2 is a well-known transcriptional repressor that acts through the deposition of the 
H3K27me3 mark and by lentiviral infection I overexpressed a subunit of the PRC2 complex, 
EZH2, responsible of the methyltransferase activity of the complex, I wanted to analyze 
eventual changes in the expression profile in these cells. I extracted RNA from cells 
expressing WT or the mutated form of EZH2 and performed RNAseq analysis on two 
biological replicates. Surprisingly, RNA-seq data showed no expression differences between 
the two samples (Fig. 13).  
 
Figure 13: Expression profiling on MEFs expressing EZH2 WT and EZH2 Y641N does not show any 
differences between samples. 
Expression profile performed on MEF Ink4a/Arf Ezh2 fl/fl in two biological replicates. Downregulated genes 
are depicted in red, upregulated genes are depicted in blue while genes that do not change in the two conditions 
are depicted in green.  
 
Since I noticed that, when growing to confluence, MEFs expressing the mutated form of 
EZH2 started to behave in a transformed-like manner, changing their morphology and 
starting to grow without contact inhibition, I decided to investigate the expression profile of 
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these cells when growing at full confluence. So, with respect to the normal condition in 
which the cells are passaged every 2 days, from here on called “growing” condition, after a 
first passage cells were left 10 days in culture subjected only to medium change, from here 
on called “confluent” condition. With this setup, firstly I checked by western blot analysis 
that the H3K27me3 mark would not show any difference in the two culturing condition (Fig. 
14A). Then, I extracted RNA from cells expressing WT or the mutated form of EZH2 in the 
two culturing conditions and performed RNAseq analysis on two biological replicates. At 
the level of gene expression, I could now appreciate a strong difference between MEFs 
expressing the WT and the Y641N form of EZH2 (Fig. 14B).  
 
 
Figure 14: Expression profile on MEFs expressing EZH2 WT and EZH2 Y641N shows differences when 
cultured at confluency. 
A: Western blot analysis using the indicated antibodies on protein extracts obtained from two biological 
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replicates of MEFs expressing EZH2 WT or EZH2 Y641N mutant. The cells are taken at normal condition of 
growing passaged every 2 days (“growing”) and after being left for 10 days in culture (“confluent”). H3 served 
as loading control. Empty lane indicates a lane in which no lysate was loaded. B: Heat-map of the expression 
profile averaged between replicates performed on “growing” and “confluent” condition. Downregulated genes 
are depicted in red, upregulated genes are depicted in blue. 
 
I then performed gene ontology enrichment analysis on the deregulated genes and found that 
up-regulated genes in the mutant were mainly implicated in epithelial cell differentiation, 
while down-regulated genes were involved into cell-cell adhesion, in line with the phenotype 
observed in the cells in culture (Fig. 15). 
 
 
Figure 15: Gene-ontology enrichment analyses reveals that upon confluency, there is downregulation of 
genes involved in cell adhesion and upregulation of genes involved in epithelial differentiation. 
GO-enrichment analysis on the obtained down-regulated (left panel) and up-regulated (right panel) gene sets 
in MEFs overexpressing the mutant form EZH2 Y641N compared to the WT one grown at confluence 
condition.  
 
I validated the RNA-seq data through reverse transcription RT-qPCR for some of the 
deregulated genes, such as Gata6, Foxa2, Tgm2 (upregulated in the mutant), and Asb4, 
Gnao1 and Gsn (downregulated in the mutant) (Fig. 16).  
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Figure 16: Validation of up- and down-regulated genes in MEFs expressing EZH2 Y641N. 
Validation of RNA-seq by RT-qPCR in regions resulted upregulated or downregulated in MEFs cells 
expressing mutated form of EZH2 Y641N compared to cells expressing EZH2 WT grown upon full 
comfluence condition of growth. 
 These results suggest that the transcriptional outcome of the aberrant deposition of 
H3K27me3 mark becomes evident when cells are subjected to stress. 
 
3.6 The effect of EZH2 GOF mutations in response to 
stimuli 
Given this kind of response, I reasoned that the transcriptional effects due to increased levels 
of H3K27me3 could become transcriptionally apparent only when cells have to 
epigenetically adapt to a particular stimulus. So I decided to test our cellular model with 
different stimuli in order to verify whether this increased amount of repressive mark could 
improve or on the contrary to injure the ability of the MEF to face to specific environmental 
change. Specifically I analyzed three different “stimuli”: i) the cooperation with an 
oncogene; ii) starvation of cells; iii) reprogramming to pluripotency.        
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3.6.1 Myc-driven Polycomb activity 
MYC (also known as c-MYC), described more than 30 years ago as a cellular homologue of 
the avian retroviral oncogene v-myc [256] is part of to the proto-oncogenic transcription 
factor family that comprise, MYC, NMYC and LMYC.  
The c-myc proto-oncogene product, MYC, is a transcription factor that binds thousands of 
genomic loci [257]. Its targets are represented by active promoters and enhancers in the 
genome. The result is that it induces an amplification of transcription [258]. Moreover, 
several studies have shown that MYC is deregulated in Burkitt's lymphomas [259, 260] and 
in non-Hodgkin B-cell lymphomas [261]. 
I wondered whether the expression of an oncogene could synergistically act with the mutated 
EZH2 in regulating transcription in cells.  
I took advantage of mouse 3T3 fibroblasts expressing a conditional Myc-oestrogen 
chimaeric receptor (3T3MycER). In this way I could induce Myc translocation into the nucleus 
upon tamoxifen administration, where it can exert its function. I proceeded by stably 
integrating EZH2-expressing lentiviral constructs also in these cells (Fig. 17). 
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Figure 17: Schematic representation of the employed lentiviral vectors and experimental approach. 
Top panel: Schematic representation of the lentiviral vector harboring either the human form of EZH2 WT or 
the mutated form of EZH2 Y641N or no transgene (Empty vector) (purple box), under the control of the EF1α 
promoter. The protein is fused with a FLAG-tag and an Internal Ribosome Entry Site (IRES) allows the 
expression of the PuroR gene. Bottom panel: scheme of the viral transduction protocol in MEFs Myc-
inducible, 3T3MycER, and selection in puromycin and description of the followed experimental procedure.  
 
First of all I assessed the level of ectopic expression of the enzyme and I tested whether the 
expression of the mutant also in these cells was able to increase the global level of 
H3K27me3. I performed western blot analyses on total extracts obtained from these cells 
lines and again I could show that only EZH2 gain of function mutants (EZH2 Y641N), but 
neither EZH2 WT, nor MEFs harboring the empty vector, showed increased H3K27me3 
levels with concomitant decrease in H3K27me2 independently from the myc induction upon 
administration of 4-OH T (Fig.18).  
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Figure 18: The mutant EZH2 Y641N alters methylation states on H3K27 also in 3T3MycER MEF. 
Immunoblots using the indicated antibodies with protein extracts obtained from 3T3MycER MEFs expressing 
the empty vector or EZH2 WT or the mutant Y641N before (EtOH) and after (100 nM OHT) Myc induction. 
H3 and Vinculin served as loading controls.  
 
Then I treated these cell lines with ethanol (vehicle control) or different concentration of 4-
OHT, 20 and 100 nM for 24 and 48 hours as schematically described in Fig. 17 observing 
the typical change in morphology encountered by cells Myc-induced driven observe in Petri-
dishes. 
I then, extracted RNA from these MEFs and checked the upregulation of classical Myc 
targets [262] upon Myc-induction, such as REEP6 and SMPD, by RT-qPCR (Fig.19). 
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Figure 19: Time and dose dependent-induction of Myc in MEFs expressing WT or mutated form of EZH2. 
Analyses of reverse transcription followed by qPCR in 3T3MycER MEFs expressing the empty vector or EZH2 
WT or mutated EZH2 Y641N without (EtOH treatment) or upon (OHT treatment) Myc induction in Myc target 
regions. 
 
To avoid saturation, I selected 24h and 100 nM concentration as the condition to be subjected 
to RNA-seq. 
In this case, I could detect very few genes differentially regulated between the MEF 
expressing the mutant EZH2 in respect to WT form upon induction of Myc (Figure 20).  
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Figure 20: Expression profile on 3T3MycER MEFs expressing EZH2 WT or the mutant Y641N 
Heat-map of the expression profile of 3T3MycER MEFs expressing the EZH2 WT or the mutant Y641N 
performed with induction of myc with 100nM OHT for 24 hours. Upregulated genes are depicted in red, 
downregulated genes are depicted in yellow. 
 
3.6.2 Starvation-driven Polycomb activity 
As a new kind of stimulus I analyzed the behavior of Ink4a/Arf-/-, Ezh2 fl/fl MEFs when 
grown in starvation condition. 
To address this point I passaged normally the cells but using different concentration of serum 
put in the culturing medium. In particular I used 0.1%, 1% and standard 10% serum 
concentration. I firstly tested the ability of the cells to live with lower amount of serum. In 
particular I tested these concentration until 72 hours (data not shown) and then I chose 24 
hours as end-time point, since afterwards cells tended to die. So, I left the cells growing for 
24 hours with different concentrations of serum and verified the exit from the cell cycle 
induced by the starvation process by FACS analysis (Fig. 21A). To do so, cells were stained 
for DNA content with PI and for replicative DNA synthesis with anti-BrdU antibody.  
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Indeed, I could observe that cells grown with lower amount of serum underwent starvation 
since the majority of cells exit from S-phase to enter in G0 phase (Fig. 21B). 
 
Figure 21: FACS analyses show exit from the cell cycle when cells are grown in starvation condition. 
A: Scheme of the followed experimental procedure. MEFs expressing EZH2 WT or Y641N cultured with 10%, 
1% or 0.1% serum and 24h later were subjected to FACS analysis. B: FACS analyses on MEFs transduced 
with empty vector or vectors expressing EZH2 WT or EZH2 Y641N cultured in presence of different 
concentrations of serum (10% or 1% or 0.1%). The analyses are representative of two biological replicates. 
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Since at 0.1% of serum I could obtain the highest fraction of cells in G0 phase, I used this 
condition and the normal serum concentration as a control to perform western blot analyses 
on total extracts. I analyzed the levels of H3K27me2 and H3K27me3 states and I could show 
that also in this condition only EZH2 gain of function mutants (EZH2 Y641N), but neither 
EZH2 WT, nor MEFs harboring the empty vector, showed increased H3K27me3 levels with 
concomitant decrease in H3K27me2 (Fig. 22). Moreover, starved MEFs, so cells mainly in 
the G0 phase, were characterized by lower amount of proteins such as Suz12 and Eed as 
previously observed in literature [201].  
 
 
Figure 22: Mutant EZH2 induces further accumulation of H3K27me3 mark in starved cells. 
Western blot analysis using the indicated antibodies on protein extracts obtained from MEFs Ink4a/Arf Ezh2 
fl/fl expressing EZH2 WT or Y641N cultured with 10% (lanes depicted in yellow in the upper part of the panel) 
or 0.1% serum (lanes depicted in purple in the upper part of the panel). The analyses are representative of two 
biological replicates. 
 
After this, I extracted RNA from these cells to performed RNA-seq analysis. Also in this 
case, the expression profile of the mutant starved cells compared to 10% serum-grew cells 
showed no differences in the expression profiles (Fig. 23).  
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Figure 23: Expression profile on MEFs expressing EZH2 WT and EZH2 Y641N shows few differences in 
starvation condition. 
Heat-map of the expression profile performed at starvation condition between MEF Ink4a Arf-/- Ezh2 fl/fl 
expressing EZH2 WT or mutant EZH2 Y641N grown at 0.1% serum. Upregulated genes are depicted in red, 
downregulated genes are depicted in yellow. 
 
3.6.3 Reprogramming 
I sought to determine whether genome-wide deposition of H3K27me3 could alter another 
induced cellular process, that is reprogramming to pluripotency. 
Indeed, in the presence of mutant EZH2 Y641N, the H3K27me3 mark spreads across the 
whole genome, so I hypothesized that this phenomenon could impair epigenetic resetting 
upon induction of cell fate reassignment by the Yamanaka factors (OCT4, SOX2, KLF4, c-
MYC) [263-265]. Also, upon spreading of this mark, pluripotency genes show increased 
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marking on their body/promoter. This is true both for early and late markers of 
reprogramming [266] (Fig. 24). 
 
 
Figure 24: Genes involved in early and late phases of reprogramming are enriched for H3K27me3 upon 
expression of mutant EZH2 Y641N in MEFs. 
Genomic snapshots of H3K27me3 ChIP-seq experiments from MEF Ink4a/arf -/- Ezh2 fl/fl transduced with 
empty vector (in black) or EZH2 WT (in blue) or mutant EZH2 Y641N (in red). 
 
So I wondered whether the increased presence of this repressive mark could have some 
effects on the reprogramming capabilities of cells expressing the mutated form of EZH2, 
like the impairment of the process itself. 
To address this point, I made use of “reprogrammable MEFs”, which were derived from 
mice carrying a double knock in of the four transgenes in the 3’-UTR of the Col1a1 locus 
under the transcriptional control of a doxycycline-responsive promoter. In these mice, also, 
the reverse tetracycline-controlled transactivator (M2-rtTA) is expressed from the Rosa26 
locus, allowing for induction of expression upon doxycycline administration [245, 246] 
(Fig.25). 
I infected these MEFs with vectors expressing the empty vector or either the WT form of 
EZH2 or the Y641F/N mutants. These vectors also carry all an independent Zs-green 
fluorescent protein expression cassette, but the empty vector carrying a Green fluorescent 
protein cassette, that allowed us to sort these cells to purity (Fig. 25). 
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Figure 25: Schematic representation of the employed lentiviral vectors and experimental approach for 
reprograming. 
Top panel: Schematic representation of lentiviral vectors harboring either the human form of EZH2 WT or 
the mutated EZH2Y641F or EZH2 Y641N forms (purple box), under the control of the EF1α promoter and in 
frame to Zs-green cassette to use as selection of integrated lentiviral vector. An empty vector carrying a GFP 
cassette was used as selection control of integrated lentiviral vector.  Bottom panel: scheme of the viral 
transduction protocol in reprogrammable OKSM (Oct3/4, Klf4, Sox2, c-Myc) MEFs used for the 
reprogramming and FACS selection of positive cells with GFP/Zs-green signal.  
 
I verified the accumulation of the H3K27me3 mark by western blot analyses on protein 
extracts derived from sorted MEFs OKSM (Fig. 26A). 
I then induced reprogramming in these cells through the use of doxycycline, and after 12 
days performed an alkaline phosphatase staining to assess reprogramming efficiency. 
Indeed, I could score a reduced efficiency in the presence of the overexpression of WT 
EZH2, and this reduction was even more marked in the presence of each of the two mutants 
(Fig. 26B-C) . 
Interestingly, colonies that emerged from the mutant EZH2-expressing MEFs showed a 
remarkable reduction in the fraction of GFP+ colonies, suggesting either silencing of the 
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vector or reprogramming of cells that were either lowly or not expressing the transgene, 
despite the initial sorting (Fig. 26D and relative quantification Fig. 26E). These results 
suggest also that the impairment in GFP+ colonies result even more strong cells expressing 
the mutant enzyme.    
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Figure 26: Mutant EZH2 impairs reprogramming. 
A: Western blot analyses of OKSM MEFs expressing the expty vector or the ones expressing EZH2 WT or 
mutated EZH2 Y641F and EZH2 Y641N.  B: Alkaline Phosphatase staining of emerging iPSC. The assay has 
been performed on MEF OKSM transduced with empty vector or EZH2 WT or mutated EZH2 Y641F and 
EZH2 Y641N, mESC were used as positive control, UT represent MEF OKSM not induced with doxycycline. 
C: Reprogramming efficiency calculated as the ratio between number of plated cells and the formed colonies. 
D: Bright field (top) and green-fluorescence (bottom) pictures of colonies after 12 days of induction. Scale bar 
1000 µm. E: Fraction of GFP+ colonies calculated in respect of total formed colonies. 
 
3.7 Validation in B-cell Lymphomas 
3.7.1 Lymphoma cells ectopically expressing or physiologically 
harboring Y641N/F EZH2 show imbalance in H3K27 
methylation status  
Finally, I wanted to validate our results in a more relevant system, diffuse large B cell 
lymphoma (DLBCL). There are different human DLBCL cells, characterized by either a 
normal activity of PRC2 enzyme EZH2 or the natural occurrence of the mutated form of 
EZH2. As representative for the first type, I used OCI-LY7 cells that are described as 
DLBCL, characterized by a reciprocal chromosomal translocation that transposes the coding 
exon 2 and 3 of the c-myc locus from chromosome 8 to chromosome 14 where it is present 
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the immunoglobulin heavy chain locus and presenting a point mutation on p53. As 
representative of the second type I have used WSU-DLCL2 that naturally harbors Y641F 
mutated form of EZH2. 
Firstly I performed western blot analysis to check the levels of H3K27 modifications in the 
different described lymphoma cells. I first used Ly7 cells. I transduced them with the same 
lentiviral vectors expressing the EZH2 WT or EZH2 mutated form Y641F and Y641N 
described in Fig. 6.  
I could score an increase in H3K27me3 and concomitant reduction of H3K27me2 levels 
(Fig. 27A). Then I analyzed WSU-DLCL2 cells that pathophisiologically harbor Y641F 
mutated form of EZH2 and could saw the same pattern of H3K27 methylation with increased 
level of H3K27me3 and concomitant decreased amount of H3K27me2 (Fig. 27B). 
 
Figure 27: Lymphoma cells overexpressing or harboring mutant EZH2 rearrange H3K27 methylation 
states. 
A: Immunoblots using the indicated antibodies with protein extracts obtained from lymphoma cells Ly7 
ectopically expressing EZH2 WT or the Y641F and Y641N mutation. H3 served as loading control. 
B: Immunoblots using the indicated antibodies with protein extracts obtained from lymphoma cells Ly7 having 
a WT form of EZH2 or WSU-DLCL2 lymhphoma physiologically harboring Y641F mutation. H3 served as 
loading control. 
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3.7.2 Distribution of H3K27 modifications in lymphoma cells 
I decided to investigate the effect of H3K27me3 accumulation by ChIP-qPCR also in the 
lymphoma system. I also performed ChIP for Suz12 subunit in order to analyze the 
occupancy of the PRC2 in these conditions in these cells. Testing the Ly7 cells expressing 
the empty vector (UT) or EZH2 WT (WT) or mutated EZH2 Y641N (Fig. 28), I could show 
that H3K27me3 and Suz12 levels were reduced at several promoter regions that are typical 
Polycomb targets in lymphomas cells. This result resembles what I previously observed in 
MEFs (Fig. 10A).  
 
Figure 28: Traditional ChIP qPCR analysis is not able to reveal increase in H3K27me3 upon expression of 
the mutant EZH2 Y641N. 
qPCR of ChIP analyses in Ly7 expressing the empty vector (UT) or EZH2 WT (WT) and mutated EZH2 
Y641N performed with the indicated antibodies on top of the histogram on typical Polycomb targets. ChIP 
enrichments are normalized to input. 
 
At this point, I performed the same analyses also in WSU-DLCL2 (Fig. 29) and SU DHL6 
(Fig. 30) cells (that pathophisiologically harbor EZH2 Y641F and EZH2 Y641N mutated 
form of EZH2 respectively) checking the same promoter regions by ChIP-qPCR for both the 
deposition of H3K27me3 and the localization of PRC2 performing a Suz12 ChIP. In these 
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experiments I used WT Ly7 cells as control since normally these latter cells present a WT 
form of EZH2. Also here I could appreciate a reduction in the deposition of the repressive 
mark and a displacement of PRC2 complex (Fig. 29-30) as happen in Ly7 transduced with 
mutant EZH2 Y641N (Fig. 27) and in MEF cells (fig.10A). 
 
 
Figure 29: ChIP qPCR analysis is not able to reveal increase in H3K27me3 in lymphoma cells naturally 
expressing mutant EZH2 Y641F enzyme. 
ChIP-qPCR analyses in Ly7 characterize by a WT form of the enzyme (used as control) and WSU-DLCL2 
physiologically harboring Y641F mutation, performed with the indicated antibodies on top of the histogram 
on typical Polycomb targets. ChIP enrichments are normalized to input. 
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Figure 30: ChIP qPCR analysis is not able to reveal increase in H3K27me3 in SU DHL6 cells that naturally 
express mutant EZH2 Y641N enzyme. 
ChIP-qPCR analyses in Ly7 characterize by a WT form of the enzyme and SU-DHL6 physiologically 
harboring Y641N mutation, performed with the indicated antibodies on top of the histogram on typical 
Polycomb targets. ChIP enrichments are normalized to input. 
 
I performed also ChIP-Rx analysis on Ly7 ectopically expressing the WT or mutated form 
of EZH2. We computed the cumulative H3K27me3 signal and observed that, after the 
normalization, H3K27me3 levels resulted increased, in agreement with the Western blot 
results and in contrast to what observed previously without the spike-in correction. I then 
analyzed the genome-wide deposition of the H3K27me3 modification along chromosomes 
length in these cells. I could observe a general increase of deposition of this modification 
not only at the promoter level (Fig. 30) but also genome wide (Fig. 31), as obtained also in 
MEFs (Fig. 11B), supporting the global increase amount of the H3K27me3 mark. 
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Figure 31: Y641N EZH2 mutant expression causes the increased deposition of H3K27me3 in DLBCL. 
A: Heat map of the normalized H3K27me3 ChIP-seq (ChIP-Rx) signal in lymphoma Ly7 cells ectopically 
expressing EZH2 WT or EZH2 Y641N mutation for H3K27me3-enriched promoters. Drosophila S2 spike-in 
normalization has been applied. B: Genome-wide deposition of the H3K27me3 modification along 
chromosomes in lymphoma cells ectopically expressing the empty vector (in yellow and blue) or EZH2 Y641N 
(in red) or physiologically harboring EZH2 Y641F mutation (in orange). 
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4. DISCUSSION 
Among cancers affecting lymphoid tissues, the most frequent disease is represented by 
diffuse large B cell lymphoma (DLBCL), accounting for about 30-40 % of the newly 
diagnosed cases of non-Hodgkin lymphomas. DLBCL is a very heterogenous disorder. It 
comprises two major subgroups: germinal center B cell (GCB) and activated B cell (ABC) 
lymphomas, each characterized by specific oncogenic pathways, translocations, recurrent 
mutations and gains and losses of genetic material and of activity of specific enzymes. GCB 
and ABC derive from subsequent stages of differentiation of germinal center B cells. In 
particular, the GCB subtype arises from centroblasts, the proliferative cells in the germinal 
center, while the ABC from a plasmablastic cell just before its egress from germinal center. 
The second most diffused type of non-Hodgkin’s lymphoma is the follicular lymphoma 
(FL). These kinds of diseases present some features that resemble the ones of the germinal 
center like DLBCL. 
Among the key player in the regulation of germinal B cells there is EZH2. The level of 
expression of this factor is higher in lymphoid progenitors, then it decreases in resting B 
cells while it increases again in germinal centers where B cells undergoes high proliferation 
and immunoglobulin affinity maturation. 
The diseases affecting these kinds of cells are different and are characterized by different 
clinical features and multiple responses to the different possible treatments. Of note, 20% of 
DLBCLs and 10% of FLs display heterozygous somatic mutations of EZH2 [225]. These 
mutations enable EZH2 to exhibit increased activity toward the accumulation of H3K27me3. 
For these reasons lots of efforts have being done in several laboratories to better understand 
these disorders in order to find novel therapies able to manage this heterogeneity.  
The work presented in this thesis aimed to better understand the molecular mechanisms 
underlying these disorders using molecular and biochemical approaches. 
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We decided to use MEF as a model to investigate these mutations in a simpler alternative 
system. We reasoned that since EZH2 is found deregulated in several cancers, we could use 
a different epigenetic context to understand the general oncogenic activity of this enzyme. 
Moreover, this same mutation has been found also in a small percentage of melanoma solid 
tumor where this mutation greatly contributes to tumorigenesis [228]. 
Regarding the deposition of H3K27me3 mark, we demonstrated that our model system 
recapitulates the global increase of this mark in respect to a decrease in H3K27me2 mark 
(Fig. 7). We showed, therefore, that this phenotype occurs also in a different developmental 
and epigenetic context in respect to B-cells such as MEFs. Furthermore, we validated our 
results in lymphoma cells. This is true for lymphomas harboring naturally a WT EZH2 (OCI-
Ly7) transduced with a mutated form of EZH2 Y641 or presenting its own mutated version 
of the enzyme: EZH2 Y641F in WSU DLCL2 (Fig. 27). That is in total accordance with 
what has been shown in literature [118, 224, 229, 230]. We showed that all the cell lines 
transduced with vectors containing the point mutation on EZH2 SET domain or taken from 
patients have increased levels of the H3K27me3 modification with respect to cells presenting 
the WT form of the enzyme [267]. Importantly, we demonstrated for the first time in our 
MEF model system that mutant EZH2 needs its WT counterpart to exert its increased activity 
toward accumulation of H3K27me3. 
Indeed, we took advantage of OHT-inducible Rosa26 CRE-ERT2, Ezh2 fl/fl, Ink4a/Arf MEF 
that allowed depletion of the WT alleles. The result is that without the WT enzyme, the cell 
is not more able to perform hyper-trimethylation of H3K27 and the accumulation of the mark 
is impaired (Fig. 8). In literature this has been demonstrated only in vitro through 
methyltransferase assay [229] while in vivo it has been shown that lymphoma cells always 
display a WT copy of the enzyme in presence of the mutant; [224]. To this regard, different 
authors showed only that by treating mutant EZH2 Y641 harboring lymphomas with 
compounds able to inhibit PRC2 activity, such as GSK343 [224] or GSK126 [231], the 
global level of H3K27me3 results drastically reduced. But these compounds affect 
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presumably both WT and mutant EZH2 present in cells thus confirming only that they are 
necessary together to have the hyper-trimethylation. Moreover, our data demonstrated that 
in presence of the hyper-activating mutation, Ezh1 is not able to compensate for Ezh2 
functionality after its depletion. This highlights for the first time, that specifically Ezh2 WT 
is necessary in order to achieve H3K27 hyper-trimethylation.  
The first ChIP analyses revealed a result that was in disagreement with the accumulation of 
H3K27me3, as shown by western blot analyses and MS (Fig. 9). Indeed both ChIP-qPCR 
and ChIP-seq data indicated a lower presence of the H3K27me3 both on Polycomb targets 
and on H3K27me3-enriched promoters, accompanied by a displacement of PRC2 (Fig. 10). 
We thought this was possibly due to: i) the choice of regions that by chance could be 
characterized by lower deposition of this mark, in the case of qPCR analyses; ii) the 
saturation of the antibody, regarding the ChIP-seq data. We hypothesized that using a certain 
amount of antibody able to recognize a certain level of antigen H3K27me3 present in a cell 
characterized by a WT EZH2, that same amount could be not sufficient to bind all the 
H3K27me3 antigens present in a cell with a mutant EZH2. This could explain the results of 
our ChIP-seq data. In order to assess this, we took advantage of a quantitative ChIP-seq 
analysis using Drosophila chromatin as reference genome [255]. By ChIP-Rx correction, we 
could show that indeed an overall spreading of the H3K27me3 mark was present in mutant-
expressing MEF. Moreover, the deposition was increased not only on the TSS of typical 
PRC2 targets but also along the entire length of all chromosomes (Fig. 11). This means that 
when we analyze and compare the tracks coming from cells harboring the WT or mutated 
form of EZH2, we can find the spread of the mark also in the gene body. Our lab [129] has 
demonstrated that PRC2 complex in embryonic stem cells is responsible for H3K27 
methylation on 80% of H3. The presented ChIP-seq data showed also that each H3K27 
methylation state is confined into spatially defined domains. In particular we demonstrated 
that H3K27me1 present at intra-genic regions favors transcription, H3K27me2 representing 
the constitutive activity of the PRC2 complex is present at inter- and intra-genic region 
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where it exerts protective function preventing firing of non-cell type specific enhancers and 
H3K27me3 is present on the TSS of genes that have to be repressed.  In our system, we have 
a model that shows that in co-presence of WT and mutant form of the enzyme the cells are 
characterized by a spread of H3K27me3 mark genome-wide at the expenses of H3K27me2 
that is the default activity of the complex. Since the H3K27me3 mark is linked to 
transcriptional repression, we wanted to investigate the functional outcome of this 
widespread mark. To address this point, we performed genome-wide transcriptomic 
analyses. Surprisingly, the first RNA-seq analyses did not point out any difference upon the 
expression of the mutant form of the enzyme (fig. 13). Our collaborators in Stefano Casola’s 
group performed a microarray analysis on lymphoma cells harboring either the WT or the 
mutant form of EZH2. The comparison between the samples also in this case did not 
highlight any difference. Unexpectedly, the mutant harboring cells were not characterized 
by an increased level of gene repression in accordance with the increased levels of the 
repressive mark. In literature different groups compared WT and mutant EZH2 harboring 
lymphoma cells trying to find the correlation between the increased PRC2 activity and the 
cancer development. McCabe and colleagues, for example, showed very few differences in 
different lymphoma cells harboring WT or mutant form of the enzyme and varying 
significantly according to the analyzed cell line [231]. Among them the authors found the 
down-regulation of genes responsible for the maturation of GC B cells toward a subsequent 
step of maturation and differentiation. In this way the cells are more prone to stably express 
a stem phenotype toward to lymphoid transformation. The same has been reported in the 
work of Beguelin and colleagues [224]. They used a lymphoma cell line, BCL1, 
characterized by a WT form of EZH2 that transduced with WT EZH2 or EZH2 Y641F or 
EZH2 Y641N, and performed ChIP-seq and RNA-seq analysis. They found (but did not 
show) a concordance between the spreading of the H3K27me3 mark and the effective 
consequent transcriptional repression. Interestingly, among negatively regulated genes, they 
found some involved in the termination of the GC reaction, such the ones IRF4-induced, and 
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in negative regulation of cell cycle, so genes involved in differentiation induction. The final 
output of this deregulation is that B-cells remain in a pro-proliferative state. 
The only case in which we could observe a difference in the transcription profile upon 
expression of the mutant form of the enzyme (EZH2 Y641N) was when cells have been 
subjected to a stressful growth condition. Upon confluence, indeed, they activate novel and 
distinct pathways of regulation to manage the stress condition (Fig. 14). What we could 
observe was the down-regulation of genes involved in the cell adhesion that is indeed what 
we could observe in Petri dish where the cells tend to lose the cell-to cell inhibition, 
resembling a transformed phenotype (Fig. 15). This behavior of the MEFs can be linked to 
the potential oncogenic response to this stressful stimulus.  
Besides those results, we could also observe the localization on the lamina of the H3K27me3 
characterizing MEFs transduced with the mutant EZH2 Y641N (Fig. 12). The nuclear lamina 
is composed of Lamin B and Lamin A that code for Lamin A and Lamin C. These protein 
components undergo PTMs and their role is to act as scaffold for the correct organization of 
the genome thus providing a structural support to the nucleus. They can interact with several 
distinct factors including proteins involved in regulating chromatin structure and 
transcription. Several papers demonstrated that Lamins cover important roles contributing, 
during cell differentiation, to the re-localization of portions of chromosomes in the nuclear 
space correlating with the expression of specific genes according to the developmental stage 
[268, 269]. In mammalian cells, from the transcription point of view, the nuclear periphery 
is considered as a transcriptionally inactive region [270-272]. Indeed, several papers showed 
that when the portion of chromatin located in the nuclear periphery should undergo 
transcription, it is rearranged and delocalized into a more inner part of nuclei. For example 
it has been demonstrated that when mouse embryonic stem cells differentiate toward neural 
fate, a large portion of chromosome 10 moves from the nuclear periphery to the inner part 
of nuclei [270] and in consequence of this there is a strong transcriptional activation of 
Mash1 gene, that code specifically for a neural transcription factor. In our experiments, we 
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scored, by immunofluorescence assay (IF), the re-localization of this increased amount of 
H3K27me3 to the nuclear periphery in cells expressing the mutated EZH2 Y641N. We 
speculate that the H3K27me3-enriched chromatin could occupy a different localization in 
the nuclei interacting in alternative way with nuclear lamina and this could be associated to 
a functional role of this increased marking. In order to study chromosome architecture with 
respect to nuclear lamina in our system, we can take advantage of Dam-ID technology. This 
method is based on the fusion of Escherichia coli DNA adenine methyltransferase (dam) to 
the protein of interest, in our case LaminB, in order to map the interaction of this protein to 
its specific target sites [273]. The expression of this fusion protein cause a preferential 
methylation of adenine in the regions surrounding the interaction site of the dam fused-to-
LaminB. The resulting adenine methylation, being not performed endogenously in most 
eukaryotes, represent a unique tag to map the protein of interest interaction sites [273]. For 
these reasons it can be a system that allows us to better investigate the newly acquired 
interaction sites of the lamina upon expression of mutant EZH2 Y641 that underlies the 
massive re-localization of H3K27me3-enriched chromatin. 
 It would be interesting to further investigate this result by mass spectrometry analysis after 
having isolated the mutant complex with respect to the WT one, in order to highlight possible 
novel interactors that could be responsible of this delocalization. To further address this 
point, we will take advantage of a technique capable of identifying long range interactions, 
namely Hi-C, that could help to decipher the relationship between histone mark localization 
and genome activity [274]. We will also use this approach in DLBCL cells to understand if 
this is a general mechanism or if it is specific of MEFs. In this context, it would be interesting 
to analyze also the deposition of marks that positively correlate with active transcription and 
the localization of RNA polymerase II. Indeed, it  has been demonstrated [275] that in the 
nuclear periphery, regions of chromatin DNase I-sensitive are present suggesting that these 
regions can accomodate poised or active genes. In this sense it would be possible the 
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presence of regions silenced but responsive to developmental cues to become activated or 
repressed. 
For these reasons, it would be very interesting to investigate the conformation of the 
chromatin solving the position of the nucleosomes and to map binding regions for specific 
transcription factor. These aims can be solved through the use of different technologies. 
These techniques include chromatin digestion using the micrococcal nuclease, that is able to 
cut nucleosome-free regions, coupled to paired-end sequencing in order to obtain a deep 
characterization of the positioning and occupancy of nucleosome. Another very useful 
technique would be the Assay for Transposase-Accessible Chromatin coupled to sequencing 
(ATAC-seq). This technique allows identifying chromatin accessible regions, to map 
nucleosome position and to find transcription factor binding sites [276].  
In our model, indeed we observed a genome-wide deposition of the H3K27me3. This mark 
is associated to repression of transcription because it is able to compact the chromatin in a 
state that is less prone to be bound by transcription factors. Indeed what I will expect is to 
find more stable nucleosomes, less accessible to interact with the different possible factors. 
To test these hypotheses, I would like to better characterize also the localization of the 
elongating Polymerase II and the deposition of the H3K27Ac and H3K36me3 through ChIP-
seq data. These two transcriptional active marks correlate usually with the presence of 
H3K27me1. Since our observations indicate a loss in the deposition of this modification, I 
will test by ATAC-seq whether upon expression of the mutant form of EZH2 Y641N, it is 
possible to highlight a change in the positioning of other main key player of transcription. 
Another interesting level of analysis would be methylation of DNA. Indeed, overall a normal 
cell presents a certain degree of DNA methylation present on the genome except in CpG 
islands that are on the other hand very diffuse on the TSS of promoters and can be bound by 
PcGs. In the case of transformed cells, it is possible to find methylated CpG islands at 
promoters which in turn can cause altered gene expression. In this regard would be very 
interesting to investigate if it is possible to score a difference in the deposition of this mark 
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upon expression of mutant PRC2 and which kind, where eventually present, of relationship 
can be present between methylated DNA and the given spreading of the H3K27me3. Also 
this analysis can be very informative and can help elucidating the group of factors that can 
interact with the complex harboring together the WT and mutant copy of EZH2. 
Since our initial hypothesis was based on the fact that the hyper-active mutation could 
silently perturb the steady state equilibrium of the cell through the accumulation of the 
repressive mark we thought to challenge the cells using different stimuli in order to 
investigate the ability of the cells to answer them. We asked whether upon expression of the 
mutant form of the enzyme the cells could answer to the stress in the same or different way 
in respect to the ones expressing the WT one. We hypothesized that in response to the stress 
triggered, cells would have induced a re-deposition of the H3K27me3.  
To address this point we analyze the ability of the cell to face firstly a deprivation of nutrients 
in the starvation condition (Fig. 21). Surprisingly, we could not observe any huge difference 
in the EZH2 mutant expressing cells compared to WT (Fig. 23) Even if this result surprised 
us it led us to think that despite the spreading of the H3K27me3 mark, this could not be 
detrimental for the cells. Indeed cells expressing mutant EZH2 are able to front the serum-
deprivation at least shortly after the beginning of the stress as cells expressing the WT form 
of the enzyme. What we can assume is that despite the spreading of this repressive mark this 
does not impair pathways that the cells would activate to respond to this particular stimulus. 
So the mutation seems not to interfere with the common ability of the cells to front nutrient 
deprivation.   
The other analysis we performed addressed an eventual cooperation between EZH2 and 
oncogenes, in this specific case with c-Myc (Fig. 17). The idea was to understand whether 
the widespread deposition of H3K27me3 mark could interact with oncogenic signals, 
mediated by the induction of myc, interfering or synergizing with it towards tumor 
transformation. 
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We took advantage of a cellular system that allows the induction of c-myc by addition of 
OHT to the medium of the cells. The RNA profiles obtained from these cells, comparing 
cells expressing WT or mutant form of EZH2, showed very few differences (Fig. 20). This, 
in agreement with the previous analyses on the starvation, suggest that also in this case it 
seems that the abundant presence of the mark does not influence in any case the 
transcriptional programs and the pathway that the cells have taken in presence or not of this 
hyper-activating mutation. These results taken together suggest that the induction of the 
oncogene myc induce the activation of the same pathways independently of the presence of 
EZH2 WT or mutant EZH2 Y641N and that also in this case the spread of the repressive 
mark does not impact on the ability of the cells to activate specific pathways in response to 
a certain stimulus. It is also possible that spreading is not stochastic but more probably 
occupies specific regions that in general do not affect the normal behavior and 
responsiveness of the cells harboring the mutation at least in these conditions.  
Lastly we decided to challenge the cells with a functional assay such as reprogramming to 
pluripotency. We took advantage of the so-called reprogrammable OKSM MEFs harboring 
the 4 Yamanaka factors, Oct4-Klf4-Sox2-Myc under the control of a doxycycline-
responsive promoter. In this way, we could induce reprogramming by addition of 
doxycycline to the culturing medium (Fig. 25). Before starting, we controlled whether in the 
presence of mutant EZH2 the H3K27me3 mark was deposited also on genes that are 
responsible for the establishment of pluripotency. We looked at the ChIP-seq data derived 
from Ink4a/Arf-/- MEF expressing the WT and mutant EZH2 Y641N form and we could 
observe an increased deposition of the repressive mark on these genes from the portion 
upstream their promoter and continuously present on their gene body (Fig. 24). So we 
hypothesized that the mutant harboring cells could be impaired in reprogramming, since it 
seemed that mutant EZH2 established additional epigenetic control. Indeed we observed a 
lower efficiency of reprogramming when cells express the mutant form of EZH2. 
Surprisingly, this effect was evident even in the presence of the WT form of this gene, even 
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if at a lower extent. Of note, we found also that, as compared to cells infected with the empty 
vector, where we can observe a 95% of green fluorescent colonies, only ~ 50% of emerged 
colonies were still expressing the green marker in cells over-expressing the WT form of the 
enzyme. This fraction was even lower (only ~12% of the colonies) in the mutant-expressing 
conditions (Fig. 26). This can be attributed to two possible explanations: i) the cell is forced 
to silence the vector to avoid the maintenance of the H3K27 hypertrimethylation or ii) the 
only cells that were reprogrammed failed to trimethylate H3K27 genome-wide. These results 
point to a barrier effect to the reprogramming process in the presence of widespread 
deposition of the H3K27me3 mark. To address these points, we will characterize the 
presence of H3K27me3 in the formed colonies. What we expect is that the emerged colonies 
would not present accumulation of the repressive mark, even in colonies expressing the 
fluorescent protein.  
Also several papers demonstrated that the reprogramming process consists of different steps. 
The early step is characterized by increased proliferation, metabolic changes, change in 
histone marks, activation of RNA processing in a stochastic process until the so-called 
deterministic, hierarchical phase take place, characterized by activation of core of 
pluripotency starting from Sox2 through Sall4 and Esrrb until Oct4 Nanog and Ezh2 itself 
and complete epigenetic resetting [266]. In our setting the experiment took 12 days. So the 
idea was that if these genes were covered by the repressive mark, it could be possible that 
they could not be activated properly, impairing in the process. Indeed we found a defective 
process in presence of already extra copies of EZH2 WT that became even more evident in 
presence of extra-copies of the mutated allele coding for EZH2 enzyme.  
Also the reverse experiment would be interesting. Indeed it could be interesting to infect 
mESC/mIPSC with EZH2-expressing vectors, verify that it would not impair the 
maintenance of pluripotency, and to perform differentiation experiments toward specific 
differentiated lineages to investigate whether the presence of the mutant can affect the 
differentiation potential of these cells. 
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Taken together these results point to a role of mutant EZH2 in “locking” cells in their 
characteristic epigenetic/transcriptional status. We speculate that the presence of mutant 
EZH2 could cause an accumulation of H3K27me3 genome-wide only in sites that are not 
transcriptionally active in that moment in the cell. This could be due to the hindrance of 
RNA-polII only in active genes. This would explain the lack of: i) down-regulation of genes 
at steady state and ii) of strong gene expression changes when cells are challenged with 
specific stimuli but are still retaining their fate, such as in the case of starvation, myc 
induction and growth in confluency.  
The only case in which we could see an altered response was during the reprogramming 
experiment. MEFs need to undergo radical transcriptional changes in order to become 
pluripotent cells and the “transcriptional lock” caused by the deposition of H3K27me3 could 
block the upregulation of pluripotency-related genes that are normally silent in MEFs. In 
this setting RNA-polII and transcription factors would fail to bind to promoters of 
pluripotency-related genes to promote their transcription.  
We speculate that this phenomenon would be occurring also in another cell fate 
determination setting, namely differentiation. Indeed, we will perform differentiation 
experiments in mESC/iPSC expressing the WT or mutant form of EZH2 (either by lentiviral 
infection or gene targeting strategies by means of the CRISPR/Cas9 platform [277, 278]), 
with the hypothesis that also in this case master regulators of differentiation will fail to be 
expressed, impairing the process.  
If proven true, this would explain the “low-differentiation” phenotype in lymphomas. We 
hypothesize that centroblasts harboring the mutant form of EZH2 would be impaired in their 
differentiation program, failing to upregulate crucial genes for B-cell maturation, and in 
combination with tumorigenic mutations this would cause uncontrolled cell proliferation, 
giving rise to tumor in patients. Indeed also in our setting, cell-to-cell contact inhibition 
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escape is induced in mutant EZH2-expressing MEFs, pointing to an additional role of this 
mutation in cell transformation. 
The results of this work, in accordance to several lines of research pointing to a re-framing 
of cancer as a developmental disease, will shed light on the molecular mechanisms that link 
epigenetic control of cell fate to tumorigenesis, paving the way to the identification of 
druggable pathways for improved care of lymphoma patients. 
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